

Queensland Clinical Guidelines

Translating evidence into best clinical practice

Maternity and Neonatal **Clinical Guideline**

Gestational diabetes mellitus (GDM)

Document title:	Gestational diabetes mellitus (GDM)
Publication date:	February 2021
Document number:	MN21.33-V4-R26
Document supplement:	The document supplement is integral to and should be read in conjunction with this guideline.
Amendments:	Full version history is supplied in the document supplement.
Amendment date:	Peer review of original document published in August 2015 Amendment May 2021
Replaces document:	MN21.33-V3-R26
Author:	Queensland Clinical Guidelines
Audience:	Health professionals in Queensland public and private maternity and neonatal services
Review date:	February 2026
Endorsed by:	Queensland Clinical Guidelines Steering Committee Statewide Maternity and Neonatal Clinical Network (Queensland)
Contact:	Email: Guidelines@health.qld.gov.au URL: www.health.qld.gov.au/qcg



Cultural acknowledgement

We acknowledge the Traditional Custodians of the land on which we work and pay our respect to the Aboriginal and Torres Strait Islander Elders past, present and emerging.

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

Recommended citation: Queensland Clinical Guidelines. Gestational diabetes mellitus (GDM). Guideline No. MN21.33-V4-R26. Queensland Health. 2021. Available from: <http://health.qld.gov.au/qcg>


© State of Queensland (Queensland Health) 2021



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au phone (07) 3234 1479.


Flow Chart: Screening and diagnosis of GDM



BGL: blood glucose level **BMI:** body mass index **DM:** diabetes mellitus **GDM:** gestational diabetes mellitus **HbA1c:** glycated haemoglobin **OGTT:** Oral glucose tolerance test **≥:** greater than or equal to **>:** greater than


*Post malabsorptive bariatric surgery includes *Roux-en-Y*, laparoscopic sleeve gastrectomy, bilio-pancreatic diversion with duodenal switch; does not include adjustable gastric banding

Flow Chart: Intrapartum management of women with GDM requiring metformin and/or insulin



BGL: blood glucose level **CS:** caesarean section **GDM:** gestational diabetes mellitus **IOL:** induction of labour
IV: intravenous **OGTT:** oral glucose tolerance test **QCG:** Queensland Clinical Guidelines **subcut:** subcutaneous
 <: less than >: greater than

Flow Chart: Postpartum care of women with GDM



BGL: blood glucose level **BF:** breast feed **CS:** caesarean section **GDM:** gestational diabetes mellitus **IV:** intravenous
OGTT: oral glucose tolerance test **QCG** Queensland Clinical Guidelines **QID** 4 times per day **subcut:** subcutaneous
>: greater than **≥:** greater than or equal to **<:** less than **≤:** less than or equal to

Table of Contents

Abbreviations	7
Definitions	8
1 Introduction	9
1.1 Prevalence	9
1.2 Diabetes classification	10
1.3 Clinical standards	11
2 Risk assessment	12
2.1 Risk factors	12
2.2 Risk reduction	12
2.3 Risks from GDM	13
2.3.1 Maternal risks from GDM	13
2.3.2 Fetal baby risks from GDM	14
3 Diabetes diagnosis	15
3.1 Diagnostic tests	15
3.2 Testing for GDM	16
3.3 Diagnosis of GDM or diabetes in pregnancy	17
3.4 Diagnostic BGL	17
4 Antenatal care	18
4.1 Antenatal care	18
4.2 Maternal care	19
4.3 Special considerations	20
4.4 Fetal surveillance	21
4.5 Psychosocial support and education	22
4.6 Self-monitoring	23
4.7 Medical nutrition therapy	24
4.8 Physical activity	25
4.8.1 Physical activity cautions and contraindications	26
5 Pharmacological therapy	27
5.1 Metformin	27
5.2 Insulin therapy	28
5.2.1 Insulin type by glycaemic abnormality	28
5.3 Hypoglycaemia	29
5.4 Education for safe self-administration of insulin therapy	30
6 Birthing	31
6.1 Considerations for birth	31
6.1.1 Birth	32
6.2 Pharmacotherapy as birth approaches	33
6.3 Intrapartum monitoring	33
6.4 Intrapartum BGL management	34
6.4.1 Insulin infusion	34
7 Postpartum care	35
7.1 Breastfeeding	36
7.2 Discharge planning	37
References	38
Appendix A: Conversion table for HbA1c measurement	43
Appendix B: Gestational weight gain	43
Appendix C: Antenatal schedule of care	44
Appendix D: Exercise and exertion	45
Acknowledgements	46

List of tables

Table 1. Diabetes classification	10
Table 2. Clinical standards	11
Table 3. GDM risk factors	12
Table 4. Risk reduction	12
Table 5. Maternal risks	13
Table 6. Fetal/baby risks.....	14
Table 7. Diagnostic tests	15
Table 8. Testing for GDM	16
Table 9. Diabetes diagnosis	17
Table 10. Blood glucose level for diagnosis	17
Table 11. Antenatal care.....	18
Table 12. Maternal care.....	19
Table 13. Special considerations.....	20
Table 14. Fetal surveillance.....	21
Table 15. Psychosocial support and education.....	22
Table 16. Self-monitoring.....	23
Table 17. Medical nutrition therapy	24
Table 18. Physical activity	25
Table 19. Physical activity cautions and contraindications.....	26
Table 20. Metformin.....	27
Table 21. Insulin therapy	28
Table 22. Insulin type by glycaemia abnormality.....	28
Table 23. Hypoglycaemia in women receiving glucose lowering medication.....	29
Table 24. Education for safe self-administration of insulin	30
Table 25. Considerations for birth	31
Table 26. Birth	32
Table 27. Pharmacotherapy as birth approaches	33
Table 28. Intrapartum monitoring	33
Table 29. Intrapartum BGL monitoring	34
Table 30. Example insulin infusion.....	34
Table 31. Postpartum BGL monitoring	35
Table 32. Breastfeeding.....	36
Table 33. Discharge planning	37

Abbreviations

AC	Abdominal circumference
ADIPS	Australasian Diabetes in Pregnancy Society
BGL	Blood glucose level
BMI	Body mass index
CI	Confidence interval
CS	Caesarean section
EFW	Estimated fetal weight
GDM	Gestational diabetes mellitus
GI	Glycaemic index
GWG	Gestational weight gain
HbA1c	Glycated haemoglobin
IFG	Impaired fasting glucose
IGT	Impaired glucose tolerance
IOL	Induction of labour
LGA	Large for gestational age
MNT	Medical nutrition therapy
NDSS	National Diabetes Services Scheme
OGTT	Oral glucose tolerance test–75 gram glucose load
PCOS	Polycystic ovarian syndrome
SGA	Small for gestational age
USS	Ultrasound scan

Definitions

Antenatal contact	In this guideline the term <i>antenatal contact</i> includes all forms of interaction between the pregnant woman and her care providers for the purpose of providing antenatal care. For example, telephone consults or SMS messaging, email, home visits, scheduled hospital appointments, videoconference or telehealth discussions.
Anti-insulin antibodies	Autoimmune marker of diabetes mellitus.
Dumping syndrome	Also known as postprandial syndrome. See below.
Gestational diabetes mellitus	In this guideline the term 'GDM' is used to refer to women with diagnostic criteria for both GDM and <i>Diabetes in Pregnancy</i> unless otherwise specified. Refer to Table 1. Diabetes classification.
Glutamic acid decarboxylase antibodies (GADA)	Autoimmune marker of diabetes mellitus
Impaired fasting glucose (IFG)	Diagnosed when the fasting BGL is higher than the normal range, but does not rise abnormally after a 75 gram glucose drink. Included in the definition of 'pre-diabetes'.
Impaired glucose tolerance (IGT)	BGL at 2 hours during an OGTT (oral glucose tolerance test) is higher than the normal range, but not high enough to diagnose type 2 diabetes. Included in the definition of 'pre-diabetes'.
Islet antigen-2 antibodies (IA-2A)	Autoimmune marker of diabetes mellitus.
Large for gestational age (LGA)	Fetal weight greater than the 90th percentile for gestational age. Consider parental ethnicity and anthropometry. ¹
Macrosomia	Birth weight greater than 4500 g. ¹
Multidisciplinary team	May include midwife, nurse practitioner, endocrinologist, obstetric physician, physician, dietitian, obstetrician, credentialled diabetes educator, general practitioner (GP), GP obstetrician, paediatrician/neonatologist, lactation consultant, Indigenous health worker, exercise physiologist or other health professional as appropriate to the clinical circumstances.
Postprandial syndrome	Occurs within 60 minutes of ingestion of food, usually rapidly absorbed carbohydrates resulting in dizziness, flushing and palpitations. Also called dumping syndrome.
Pre/postprandial	Before/after eating a meal.
Pre-diabetes	Blood glucose levels are higher than normal, but not at a level to diagnose type 2 diabetes. Includes impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).
Psychosocial services	Any services, organisation (government or non-government) or health discipline that provides counselling, support, mental wellbeing assessment, psychiatric care, peer support, or other psychological or psychosocial care.
Small for gestational age (SGA)	Birth weight below the 10th percentile ¹ , not necessarily implying fetal growth restriction as baby may be constitutionally small.
Suspected fetal macrosomia	Ultrasound scan estimated fetal weight and/or abdominal circumference greater than 95th percentile for gestation. ²

1 Introduction

Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy.³⁻⁵ It is defined as glucose intolerance that is first diagnosed or recognised during pregnancy, and does not meet criteria for overt diabetes outside pregnancy. If glucose levels are high enough to be consistent with a diagnosis of diabetes outside pregnancy, the term 'Diabetes in Pregnancy' (DIP) is preferred. DIP commonly represents undiagnosed diabetes mellitus detected for the first time during pregnancy^{6,7}, but the diagnosis generally requires confirmation in the postpartum period. Although GDM usually resolves following birth, it is associated with significant morbidities for the woman and baby in the perinatal period, and in the long term.^{5,8-17}

There is widespread (but not universal) consensus on the diagnostic criteria for GDM used in this guideline. This includes endorsement by a significant number of professional organisations including Australasian Diabetes in Pregnancy Society (ADIPS)⁷, National Health and Medical Research Council¹⁸, Australian College of Midwives, International Association of Diabetes and Pregnancy Study Group¹⁹, Australian Diabetes Educators Association, The Royal Australian and New Zealand College of Obstetricians and Gynaecologists²⁰, The International Federation of Gynecology and Obstetrics²¹ and the World Health Organisation.⁴

1.1 Prevalence

The number of women diagnosed with GDM is increasing. This may reflect the increase in both maternal age and body mass index (BMI) of the pregnant population, and/or be associated with changing definitions of GDM.²²

- Queensland incidence of GDM (as at January 31 2020) was 13% in 2018²³
- Australian incidence of GDM was 14% of women birthing in hospital in 2018²²
- Incidence of GDM has tripled since 2000–2001²²
 - o The incidence of GDM increases with the level of socioeconomic disadvantage (21% compared with 13%)²⁴
- Incidence of GDM for Aboriginal and/or Torres Strait Islander women was similar to the rate in non-Indigenous women (adjusted for differences in age structure of each group)²²
- Older women (45–49 years) were more than four times likely to have a GDM diagnosis²⁴
- Treatment in 2016–2017:
 - o 32% required insulin therapy²⁴
 - o 8% required oral hypoglycaemia medications²⁴

1.2 Diabetes classification

Table 1. Diabetes classification

Classification	Description
GDM^{4,6}	- Glucose intolerance with onset or first recognition during pregnancy - Elevated plasma glucose levels less severe than overt diabetes - Refer to Table 10. Blood glucose level
Diabetes in pregnancy^{4,6}	- Hyperglycaemia onset or first recognition during pregnancy - Plasma glucose levels exceed the threshold(s) for diagnosis of diabetes outside pregnancy - May indicate undiagnosed or pre-existing diabetes outside pregnancy, but a definitive diagnosis of non-gestational diabetes cannot be made until the postpartum period - Additional management (beyond that required for lower abnormal plasma glucose levels) is required - Refer to Table 10. Blood glucose level
*Type 1^{4,6}	- The body no longer makes its own insulin and cannot convert glucose into energy, resulting from β cell destruction that leads to near or absolute insulin deficiency - Commonly accompanied by autoimmune markers including anti-GAD, anti-IA-2A antibodies and anti-insulin antibodies - Daily insulin via injection or a continuous subcutaneous insulin infusion (CSII) pump is required - Diagnosis is usually established outside of pregnancy (before or after)
*Type 2⁶	- Hyperglycaemia resulting from insulin resistance and/or insufficient production of insulin - Lifestyle modification (diet and physical activity) is the cornerstone of management - Oral hypoglycaemic medication and/or insulin therapy is usually required - If woman is on non-insulin injectables (e.g. GLP1 agonists) these are ceased at pregnancy diagnosis, due to lack of safety data for use during pregnancy - Diagnosis is usually established outside of pregnancy (before or after) or may present as diabetes in pregnancy (confirm diagnosis postpartum) - Elevated HbA1c in first trimester [refer to Table 10. Blood glucose level for diagnosis]
*Pre-diabetes^{6,25}	- A condition in which blood glucose levels are higher than normal but not high enough to be diagnostic of diabetes - Includes impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - Diagnosis is established outside of pregnancy (before or after)

*Management not discussed in this guideline

1.3 Clinical standards

Table 2. Clinical standards

Aspect	Consideration
Clinical care	- Develop locally agreed protocols to support management including²⁶: - Consultation mechanisms, or processes with higher service capabilities including the use of telehealth - Standardised forms or communications that support care planning (e.g. peripartum insulin management plan) - Mechanisms for offering dietary advice, blood glucose monitoring and blood glucose lowering therapy as indicated - Support clinical staff to develop communication skills that enable positive and non-judgemental discussions about obesity and weight gain with pregnant women²⁷ - Consider access to local resources (e.g. anaesthetic services, dietetic services, consulting rooms) - Refer to <i>QCG Standard care guideline</i>²⁸
Model of care	- Individualise care for the woman¹⁸ - Provide common philosophy involving shared understanding of care pathways by all health care providers involved in the women's care^{18,29} - Collaborative model of care that supports continuity of midwifery care improves maternal and neonatal outcomes and is suitable for high risk women^{30,31} - Establish referral pathways and consultation mechanisms with higher level services as required³² - Establish local criteria for low risk GDM model of care: - Consider local experience and expertise in management of GDM, as well as criteria that prompts a review or signals that a change in model of care may be required - The following groups of women are not suitable for care in a low risk model: - Pre-existing diabetes (type 1 or type 2) - Diagnosis of diabetes in pregnancy - GDM requiring pharmacological therapy - GDM with other medical or pregnancy complications - A multidisciplinary team approach is ideal^{33,34} [refer to Definitions] - Women with well managed diet controlled GDM and no other risk factors for known complications, may be suitable for low risk models of care although closer surveillance/more frequent antenatal contact is still required - Midwifery³¹ and general practitioner (GP) continuity of care models compliment high risk obstetric care - Increased breastfeeding rates have been reported in women with diabetes in pregnancy who receive consistent support³⁵
Diabetes related products	- Establish access to free or subsidised blood glucose meter programs (e.g. via manufacturers) - Advise to register (requires approved clinician support) with National Diabetes Services Scheme (NDSS)³⁶ to access diabetes related products at subsidised cost - Free registration is open to all Australian citizens and others who are Medicare eligible³⁶ - Registration with National Gestational Diabetes Register aids accurate national data collection, and creates a recall system for women and their GP about the importance of postnatal oral glucose tolerance test (OGTT), and ongoing surveillance for type 2 diabetes

2 Risk assessment

Abnormalities of glucose tolerance have immediate, short-term, and long-term implications for the health of the woman and her baby²⁴, and may be prevented by adequate treatment.^{6,14} Discuss with all women the benefits of achieving or maintaining a healthy lifestyle (e.g. nutrition, gestational weight gain and physical activity).^{14,26}

2.1 Risk factors

Assess all women early in their pregnancy for risk factors associated with gestational diabetes.⁷

Table 3. GDM risk factors

Aspect	Risk factors
Context	It is not known if all risk factors are of equivalent predictive value⁷
Ethnicity ^{1,7,37}	- Greater risk for women who are: - Asian - Indian subcontinental (India, Pakistan, Bangladesh, Nepal, Sri Lanka, Bhutan, and the Maldives) - Aboriginal and/or Torres Strait Islander - Pacific Islander - Maori - Middle Eastern - Non-white African
Maternal history	- Previously elevated blood glucose level^{1,7,12} or previous GDM^{1,12,37,38} - Maternal age greater than or equal to 40 years^{7,37} - Obesity (BMI greater than 30 kg/m²)^{1,7,12,14,37} - Family history of diabetes mellitus (first degree relative with diabetes or sister with GDM)^{1,14,37} - Previous large for gestational age (LGA) baby⁷ [refer to Definitions] - Polycystic ovarian syndrome^{1,7,12,37} - Previous perinatal loss^{1,7,12,14,37} - Medications—corticosteroids^{1,12}, antipsychotics⁷ - Multiple pregnancy³⁹

2.2 Risk reduction

Table 4. Risk reduction

Aspect	Consideration
Context	- Incidence of GDM may be reduced by lifestyle interventions started before the 15th week of pregnancy (RR 0.80, 95% CI 0.66–0.97) when compared to standard care⁴⁰ - Not effective for women later in pregnancy⁴⁰ - Probiotics have not shown any proven role in GDM prevention in pregnant women who are overweight or have obesity⁴¹ - Low vitamin D levels: - Have been associated with increased risk of developing GDM - Have been associated with sub-optimal blood glucose levels (BGL) in women with GDM in third trimester¹⁵ - Require supplementation in women from populations at risk to reduce the risk of GDM^{42,43} - If woman has a low baseline vitamin D (less than 50 nmol/L) supplementation may reduce the risk of GDM⁴⁴ - It is unclear if physical activity interventions/exercise during pregnancy prevent GDM, but they do limit excessive gestational weight gain (GWG), and reduce the risk of caesarean birth and of having a LGA baby^{45,46}
Recommendation	Advise women that regular physical activity and healthy eating before and during pregnancy help to limit excessive weight gain⁴⁷

2.3 Risks from GDM

2.3.1 Maternal risks from GDM

Table 5. Maternal risks

Aspect	Consideration
Context	• There is a clear relationship between increased plasma glucose levels during pregnancy, and adverse maternal and fetal outcomes independent of other known factors for these outcomes^{5,8,48} • Continuum of risk for adverse pregnancy outcomes is across maternal glucose levels and includes levels below diagnostic values for GDM^{4,8,49} • There is variable quality and conflicting evidence about the degree of risk conferred by maternal hyperglycaemia on maternal and fetal outcomes⁵⁰
Maternal short term risks	• Pre-eclampsia^{8,12,14,24,48} • Induced labour^{24,48} • Operative birth^{12,15,24} • Hypertension in pregnancy²⁴ • Caesarean section^{24,48} • Preterm labour and birth²⁴ • Polyhydramnios⁵¹ • Post-partum haemorrhage⁵¹ • Infection⁵¹ • Birth trauma
Maternal long term risks	• Recurrent GDM in subsequent pregnancies^{52,53} ◦ Magnitude of risk increased with the number of prior pregnancies with GDM ◦ Increased risk of developing GDM in second pregnancy (OR, 13.2; 95% CI, 12.0–14.6)⁵⁴ ◦ Rate of GDM in second and third pregnancies 4.2–4.7%⁵⁴ • Progression to type 2 diabetes^{11,15} ◦ About 5–6.5% within 6 months of birthing⁵⁵ ◦ 10.7% if untreated [OR 7.63; 95% CI, 5.33–10.95]⁵ • Risk of developing diabetes or pre-diabetes at mean of 11.4 years post GDM affected pregnancy¹¹ ◦ 52.2% (OR 3.44, 95% CI, 2.85 to 4.14) • Increased risk of developing a disorder of glucose metabolism¹¹ (e.g. IFG, IGT or type 2 diabetes) • Development of metabolic syndrome⁴⁸ • Development of cardiovascular disease^{15,56} • Renal disease⁵⁶

2.3.2 Fetal baby risks from GDM

Table 6. Fetal/baby risks

Aspect	Consideration
Fetal/newborn baby short term risks	• Prematurity^{8,15}, especially if maternal hyperglycaemia severe and required treatment with insulin¹³ • Macrosomia^{8,12,15-17} especially if maternal hyperglycaemia severe and required treatment with insulin^{13,16,48} • Increased newborn weight^{8,57} and adiposity⁵⁷ • Birth trauma—risk increases as fetal growth accelerates and weight increases^{8,12,16,17} - o Bone fracture - o Nerve palsy • Hypoglycaemia^{8,15} • Respiratory distress syndrome^{15,17} • Jaundice^{8,16} • Hypocalcaemia¹⁵ • Polycythaemia/hyperviscosity⁵⁸ • Cardiac anomalies including hypertrophic cardiomyopathy and consequent left ventricular outflow tract obstruction⁵⁹ • Stillbirth (late) if GDM is uncontrolled or not treated resulting in raised fasting plasma glucose⁶⁰
Baby long term risks	• Increased risk for: - o Impaired glucose tolerance¹⁵ - o Development of type 2 diabetes¹⁵ - o Overweight and obesity^{5,11,15,61} • Insufficient evidence for which strategy for management of diabetes in pregnancy reduces long term risks for the baby⁶²

3 Diabetes diagnosis

3.1 Diagnostic tests

Table 7. Diagnostic tests

Aspect	Consideration
Context	- Use a single set of diagnostic criteria for GDM and diabetes in pregnancy [refer to Table 10. Blood glucose level for diagnosis] - Some professional bodies recommend using non-pregnancy glucose reference ranges in first trimester—not endorsed by ADIPS⁷ - Not all women with mild elevations of glucose (particularly fasting glucose) in early pregnancy will progress to severe glucose abnormalities⁶³ - Individualised management is required
OGTT	- Main value is to identify women with any degree of hyperglycaemia¹⁹ - Suitable for use in the first trimester and at 24–28 weeks gestation - There is lack of evidence based targets for first trimester to diagnose GDM¹⁴ - Diagnosis by OGTT results in better perinatal outcomes (e.g. LGA, neonatal unit admissions and neonatal hypoglycaemia) when compared with the two step glucose challenge test⁶⁴
HbA1c	- HbA1c is only suitable in first trimester for women with risk factors¹⁸, before erythrocyte formation starts to increase and basal glucose levels fall - Limited use for GDM diagnosis, management or postpartum assessment⁷ because of low test sensitivity - Unlikely to identify women with milder degrees of hyperglycaemia, GDM or reflect rapidly developing insulin resistance - Only useful if woman also has fasting plasma glucose level (PGL) as each has a different sensitivity for GDM diagnosis - Known haemoglobinopathy may underestimate HbA1c due to increased red cell turnover⁶⁵ - Main value is to identify women likely to have pre-existing glucose abnormalities (e.g. type 2 diabetes) - Refer to Appendix A: Conversion table for HbA1c measurement
Plasma glucose	- Fasting (8–12 hours after eating) is used as it is less influenced by time and recent food intake⁶⁶ - Fasting PGL at 24–28 weeks gestation only recommended as suggested below*
Test type recommendation	- OGTT is the preferred diagnostic test for pregnant women with or without risk factors⁷ *During COVID-19 pandemic a modified two step testing protocol⁶⁷ was implemented to reduce community exposure risk, but requires further evaluation before adoption as standard care: - If fasting PGL - Less than 4.7 mmol/L, normal result 4.7–5.0 mmol/L OGTT indicated - Greater than 5 mmol/L, diagnostic of GDM - There may be circumstances where HbA1c and fasting blood glucose are appropriate in the first trimester including: - Woman is at high risk of underlying type 2 diabetes (e.g. Aboriginal and/or Torres Strait Islander) - If the woman is unable to tolerate the OGTT (e.g. due to morning sickness, hyperemesis) - Opportunistic care is appropriate due to potential for woman declining or unable to complete OGTT - OGTT is not practical due to clinical, geographical or logistical circumstances - May be suitable for women who have had bariatric surgery and are at risk of postprandial syndrome (“dumping syndrome”)⁶⁸ - Woman is taking metformin for polycystic ovarian syndrome (PCOS)⁶⁹

3.2 Testing for GDM

Offer all women for GDM during pregnancy as outlined in Table 8. Testing for GDM. The oral glucose challenge test is no longer recommended.^{4,7,19-21}

Table 8. Testing for GDM

Aspect	Consideration
Context	- Advise the woman having an OGTT to^{66,70}: - Maintain a normal diet - Fast for 8–14 hours before the OGTT - Drink water during fasting to prevent dehydration - Continue any usual medications [refer to Maternal medications* below]
With risk factor(s)	- Perform an early OGTT (or HbA1c) with first antenatal bloods or at the first antenatal visit (in the first trimester)^{7,19} - If the early OGTT (or HbA1c) is normal, repeat OGTT at 24–28 weeks gestation as for women with no risk factors¹⁹
Post-bariatric surgery	- If woman has had laparoscopic adjustable gastric banding (LAGB) or sleeve gastrectomy (SG) - Usual GDM testing⁶⁸ may be possible - OGTT at 24–28 weeks gestation - If gastric band is tight or the woman is vomiting, OGTT unlikely to be tolerated - If post malabsorptive BS (e.g. Roux-En-Y gastric bypass (RYGB), or biliopancreatic diversion)⁶⁸ an OGTT is not suitable due to altered gastric emptying including postprandial syndrome (“dumping syndrome”)⁶⁸ - In first trimester consider: - If history of diabetes or other risk factors^{68,71}, a fasting BGL and HbA1c - If HbA1c greater than or equal to 48 mmol/mol (6.5%), or fasting BGL is greater than or equal to 7.0 mmol/L⁷¹ treating woman as if has type 2 diabetes - If history of diabetes, repeat HbA1c⁷¹ - In second trimester consider: - Fasting BGL between 24–28 weeks gestation, and if BGL 4.6–5 mmol/L recommend fasting and postprandial BGL for one to two weeks⁶⁸ (self-monitoring) - In third trimester: - If evidence of fetal hyperinsulinaemia is present on growth scan, repeat testing⁷¹ [refer to Table 14. Fetal surveillance] - Refer to Queensland Clinical Guidelines: <i>Obesity in pregnancy</i>⁷²
No risk factor(s)	Routinely recommend an OGTT to all pregnant women, who are not known to have GDM, at 24–28 weeks gestational age^{7,19}
Maternal medications*	- Do not perform an OGTT within one week of steroids (betamethasone/dexamethasone) administration - If receiving steroids monitor BGLs - If taking metformin for PCOS, OGTT results may be misleading
If OGTT declined	- Fasting glucose test may be an alternative although this will only give partial information on glucose metabolism - Refer to Table 7. Diagnostic tests

3.3 Diagnosis of GDM or diabetes in pregnancy

Table 9. Diabetes diagnosis

Aspect	Consideration
GDM	- Diagnosis is based on the results of the fasting 75 g OGTT during pregnancy - One or more elevated level(s) is sufficient for a diagnosis of GDM^{7,19} - If fasting blood glucose test, or HbA1c (e.g. in woman who has had bariatric surgery or other reason), is an elevated value this is diagnostic of GDM^{7,19} - Refer to Table 10. Blood glucose level for diagnosis
Diabetes in pregnancy	- Diagnosis based on glucose levels exceeding the threshold for diagnosis of diabetes^{6,34} [refer to Table 10. Blood glucose level for diagnosis] - If diabetes in pregnancy: - Manage woman in a centre/clinic with experience in the management of pre-existing diabetes in pregnancy¹ (not suitable for a low risk model of diabetes care) - Consider screening for complications of diabetes (e.g. retinopathy and nephropathy)¹ - Higher risk of pregnancy complications¹ - Consider low dose aspirin for pre-eclampsia prevention⁷³ [refer to Queensland Clinical Guidelines <i>Hypertension and pregnancy</i>⁷⁴ - Postpartum testing required to confirm or exclude non-gestational diabetes¹

3.4 Diagnostic BGL

Worldwide (including Australia), HbA1c measurement and reporting has been standardised using Systeme International (SI) units. Refer to Appendix A: Conversion table for HbA1c measurement

Table 10. Blood glucose level for diagnosis

Diagnosis	Test	Test result
*GDM^{4,7,19,21}	BGL	Plasma glucose level (one or more)
	Fasting	5.1–6.9 mmol/L
	1 hour	Greater than or equal to 10.0 mmol/L
	2 hour	8.5–11.0 mmol/L
	HbA1c	- Limited evidence suggests that HbA1c greater than or equal to 41 mmol/mol and less than 48 mmol/mol in early pregnancy sufficient to diagnose GDM⁷⁵ - Lower values do not exclude GDM^{76,77}
Diabetes in pregnancy (DIP)^{4,7,19,21}	BGL	Plasma glucose level (one or more)
	Fasting	Greater than or equal to 7.0 mmol/L
	1 hour	<i>A one hour level is not used</i>
	2 hour	Greater than or equal to 11.1 mmol/L
	Random	- Greater than or equal to 11.1 mmol/L - Confirm with additional standardised testing
	HbA1c	Greater than or equal to 48 mmol/mol or 6.5% in early pregnancy^{19,68}

*Refer also to Table 7. Diagnostic tests

4 Antenatal care

Objectives for antenatal care of women diagnosed with GDM:

- Effectively manage of the diabetes
- Monitor for maternal complications
- Prevent fetal/neonatal complications
- Provide routine antenatal care^{33,34,78}

Refer to Table 2. Clinical standards.

4.1 Antenatal care

Table 11. Antenatal care

Aspect	Consideration
Antenatal contact	• Individualise the antenatal schedule of contact according to clinical circumstances^{18,33} • If BGLs are suboptimal or there are complicating factors (e.g. hypertension, pre-eclampsia, macrosomia, intrauterine growth restriction) more frequent antenatal contact is required • GDM or DIP diagnosed before 16 weeks gestational age requires increased surveillance and monitoring, as likely to be pre-pregnancy pre-diabetes or diabetes³⁷ • Refer to Appendix B: Gestational weight gain
Initial clinical assessment all GDM	• All routine antenatal assessments are indicated throughout pregnancy • Develop an individualised plan of care with women whose pregnancy is complicated with diabetes³³ ◦ Review and update the plan at frequent intervals • Recommend ultrasound scan (USS) at 28+0–30+6 weeks gestation³³ to assess fetal growth including fetal abdominal circumference (AC), and to establish a baseline for future evaluation • Order laboratory evaluation of serum creatinine
At GDM diagnosis	• Review history—previous GDM, medications • Refer for diabetes educator and dietitian consult within one week of diagnosis • Provide psychosocial assessment and support—refer as required • Commence BGL self-monitoring • Review pre-pregnancy BMI¹ and discuss individualised healthy weight gain targets in pregnancy • Discuss lifestyle factors including physical exercise and smoking cessation (if applicable) • Provide request forms for USS and laboratory investigations including serum creatinine at 28+0–30+6 weeks gestation • If pharmacological therapy commenced: ◦ Follow-up contact within three days by health care provider ◦ Weekly diabetes educator review • Review timing of next contact (at clinic, or by phone, telehealth or email) ◦ Fortnightly until 36+0 weeks gestation ◦ Weekly until birth ◦ Increase as indicated • If obesity also present consider anaesthetist review [refer to Queensland Clinical Guidelines <i>Obesity in pregnancy</i>⁷²]

4.2 Maternal care

Table 12. Maternal care

Aspect	Consideration
Monitoring	- Women with GDM require increased surveillance throughout pregnancy - Consider other risk factors to determine model of care and frequency of antenatal contact - Maintain a high index of suspicion for associated conditions (e.g. pre-eclampsia) - Refer to Table 5. Maternal risks - At each antenatal contact: - Reassess if increased antenatal contact with the multidisciplinary team members is required - Review BGL self-monitoring records - Assess psychosocial needs, and offer support or referral as appropriate for the woman—consider stress related to GDM diagnosis and management - Review lifestyle factors—weight gain trends, diet, exercise, smoking cessation (if applicable) - Test urine for proteinuria - USS scan as indicated [refer to Table 14. Fetal surveillance] - Women participating in Ramadan fasting will require a practical approach and close consultation with the health care team⁷⁹ - Ramadan fasting is associated with lower mean glucose levels and higher rates of hypoglycaemia than non-fasting women⁸⁰
Weight	- Pre-pregnancy obesity and excessive GWG are independent risk factors for fetal macrosomia in women with GDM⁸¹ - Compared to normal weight women without GDM⁸¹ - Normal weight women with GDM are 1.94 times as likely (95%CI 1.43–2.68) to have LGA baby - Obese women with GDM are 5.47 times as likely (95% CI 4.34–6.90) to have LGA baby - Discuss GWG in a sensitive and non-judgemental manner that minimises maternal anxiety²⁷ - Refer to Table 5. Maternal risks - Calculate pre-pregnancy BMI at the first opportunity - Recommend and discuss desirable GWG and rate of GWG - GWG recommendations for the woman with GDM are the same as other pregnant women - Refer to Appendix C: Antenatal schedule of care - Refer to Queensland Clinical Guideline <i>Obesity in pregnancy</i>⁷² - Weigh woman at each visit - Rapid GWG may indicate polyhydramnios - Inadequate GWG or weight loss may reflect inappropriate restriction of dietary intake and/or improved diet quality - If woman not already under dietetic care, consider referral to a dietitian - Refer to Australian Dietary Guidelines^{72,82}
Urine testing	- Test urine at each antenatal visit³³ - Proteinuria may indicate other complications (e.g. pre-eclampsia or renal impairment or nephropathy)⁸³ - Glycosuria is not a reliable indicator of inadequate glycaemic management⁸⁴

4.3 Special considerations

Table 13. Special considerations

Aspect	Consideration
Breastfeeding preparation	- Advise women of benefits of breastfeeding after GDM, including prevention of newborn hypoglycaemia, childhood obesity and diabetes for women and child¹ - Advise women who are considered low risk to express antenatally - Not recommended for women with a history of antepartum haemorrhage or placenta praevia, more than one previous caesarean section (CS), fetal growth restriction, documented macrosomia, polyhydramnios, hypertension, fetal compromise, or other serious maternal medical condition⁸⁵ - There was no harm identified in a study (DAME trial) of advising low risk women about the benefits of routine antenatal expression of breast milk⁸⁵ - There are potential benefits for the newborn baby⁸⁶ - For low risk women with GDM or DIP, advise about commencing hand expression (for 10 minutes no more than twice per day) from 36+0 weeks of gestation⁸⁵ - Refer to local policies and guidelines
Diabetes in pregnancy	- Review and/or recommend morphology USS as there may be an increased risk of fetal congenital anomaly³⁴ - If BGL above target levels in first trimester offer tertiary morphology USS - Test for retinopathy³³ as the presence of these are associated with a substantially increased risk of developing pre-eclampsia - Recommend optometrist or ophthalmologist review^{6,34} - Test for microalbuminuria²⁶ as worsening nephropathy and super-imposed pre-eclampsia are most common cause of preterm birth in women with GDM²⁶ - Consider starting pre-eclampsia prophylaxis (aspirin and/or calcium supplement) prior to 16+0 weeks gestation⁷³ - Refer to Queensland Clinical Guidelines <i>Hypertension and pregnancy</i>⁷⁴
Post bariatric surgery	- Screen for micronutrient deficiencies⁷¹ - Refer woman early in pregnancy for specialist dietary advice to optimise micronutrient supplementation, dietary intake and symptom management⁷¹ - If woman has had gastric banding surgery: - Increased risk of small for gestational age (SGA) baby [refer to Table 14. Fetal surveillance] - In first trimester, refer for management of gastric band in case of hyperemesis and to prevent nutrient deficiency⁷¹ - In second and third trimesters assess GWG and fetal growth—band may require adjusting⁷¹ - Refer to Queensland Clinical Guidelines <i>Term small for gestational age baby</i>⁸⁷

4.4 Fetal surveillance

Table 14. Fetal surveillance

Aspect	Consideration
Context	• There is limited evidence or consensus regarding specific antepartum tests or their frequency, for fetal wellbeing⁸⁸ • Monitoring type and frequency is influenced by the presence of other pregnancy complications (e.g. antepartum haemorrhage, pre-eclampsia, fetal growth restriction) as well as severity of maternal hyperglycaemia⁸⁹ • Fetal AC on USS greater than or equal to 75th percentile for gestational age, measured at 29+0 to 33+6 weeks gestation, correlates with fetal hyperinsulinaemia and an increased risk for birth of an LGA infant⁹⁰ - o May require more intensive glucose lowering therapy⁹⁰ - o If fetal USS shows normal growth is maintained, consider relaxing glycaemic targets⁹⁰
Fetal growth and wellbeing	• Perform clinical assessment of fetal size and amniotic fluid volume^{12,91} • Assess the fetal response to maternal GDM by USS measurement of fetal AC commencing at 28+0–30+6 weeks gestation^{12,92} • Longitudinal growth assessment is superior to a single measurement late in pregnancy if abnormal on first scan • Accelerating AC especially if greater than 95th percentile is clinically significant • Consider 2–4 weekly USS for women with unstable diabetes or who require pharmacological therapy or comorbid risk factors (e.g. obesity, hypertension, LGA or SGA, previous stillbirth)¹² - o If fetal growth restriction is suspected, follow usual imaging fetal surveillance including umbilical artery and middle cerebral artery Doppler¹² • If excessive fetal growth or AC above 75th centile is detected, consider more intensive management^{90,93} which <i>may</i> include: - o Lower blood glucose targets for glycaemic management - o Addition of pharmacologic therapy - o Altered frequency of scans and interpretation • Obstetric USS may be suboptimal in women with GDM and/or post-bariatric surgery - o May affect accuracy of estimated fetal weight (EFW) ▪ EFW generally within 10% of actual birthweight - o Remains clinically reliable to identify LGA and SGA

4.5 Psychosocial support and education

Table 15. Psychosocial support and education

Aspect	Consideration
Context	- Emotional well-being is an important part of diabetes care and self-management⁹⁴ - Rapport between the woman and the health care provider can enhance compliance⁹⁵ - Barriers to effective treatment response in women with GDM include depression, eating disorders, stress and anxiety⁹⁶
Information and education	- Individualise the approach to management and consider⁹⁵ - Cultural/language background - Learning ability and style of learning (e.g. written information, visual) - Family and social circumstances - Provide women and their families comprehensive information about GDM to aid in self-management including³⁴: - Implications of GDM for the woman and her baby (short and long-term) - Dietary and physical activity recommendations [refer to Table 18. Physical activity] - Self-monitoring of blood glucose procedures and targets - Advice about seeking urgent medical advice if they become hyperglycaemic or unwell - Importance of long term follow-up - Provide information about NDSS website for additional resources - Discuss risk of newborn hypoglycaemia, and need for BGL monitoring and management of baby after birth for at least the first 24 hours - Provide Queensland Clinical Guideline parent information <i>Newborn hypoglycaemia</i>⁹⁷
Psychosocial support	- Support women to make positive lifestyle changes - Diagnosis of GDM and education about the short and long term risks of GDM and type 2 diabetes can motivate women to undertake long-lasting changes⁹⁸ - Perform a psychosocial assessment and refer women as required to social work or mental health services for support - Utilise strategies to support behaviour change including self-monitoring, goal setting, problem solving and motivational interviewing⁹⁹

4.6 Self-monitoring

Results from BGL self-monitoring form only part of the clinical decision making regarding the need for pharmacological treatment for an individual woman. Also consider the potential for improved glucose control with medical nutrition therapy, enhanced physical activity and assessment of fetal growth. Refer to Table 14. Fetal surveillance, Table 17. Medical nutrition therapy and Table 18. Physical activity.

Table 16. Self-monitoring

Aspect	Consideration
Context	- Self-monitoring of BGLs before and after meals is a key part of the management of GDM - Self-monitoring of BGLs can improve glycaemic management by providing a baseline from which to evaluate the effectiveness of interventions - There is limited evidence about optimal treatment targets for self-monitoring capillary BGL⁷ - The two major studies in this area^{78,100} used different targets, and a systematic review¹⁰¹ suggested the targets used were higher than the levels found in normal pregnancy - Targets currently recommended by ADIPS are not backed by strong evidence and are noted as an area for future research - Flash monitoring and continuous glucose monitoring are not Therapeutic Goods Administration (TGA) approved¹⁰² for GDM management¹⁰³
BGL self-monitoring	- Recommend BGL self-monitoring to the woman diagnosed with GDM - Blood glucose meter is for the woman's individual use only - Advise the woman to bring blood glucose meter and diary to each appointment for review and download of data - Provide individual or group teaching about self-monitoring of blood glucose by a clinician experienced in diabetes education including: - Importance of hand washing - Use of blood glucose meter - Use of lancet device and safe disposal of sharps - Recording of BGL results (e.g. BGL diary in paper or electronic form) - Potential causes of errors in monitoring techniques and results - Understanding results and the impact of exercise, dietary intake, stress and illness - Use of a food diary for improved awareness of dietary intake and effect on BGL - Initially, advise BGL self-monitoring four times per day, either: - Before breakfast and one hour postprandial (each main meal) or - Before breakfast and two hours postprandial (each main meal) - Reduce or increase BGL self-monitoring frequency depending on glycaemic targets achieved and progress of pregnancy (e.g. if woman is 37+0 weeks or more gestation, glycaemic targets are managed with diet, and baby is normally grown reduce BGL monitoring)
BGL targets	- Trend patterns and mean values of BGL are more important than individual results (which may reflect dietary or lifestyle related factors) - Suggested capillary BGL targets (not supported by strong evidence) are⁷: - Fasting—less than or equal to 5.0 mmol/L 1 hour after commencing meal—less than or equal to 7.4 mmol/L 2 hours after commencing meal—less than or equal to 6.7 mmol/L - If BGL is elevated on two occasions at the same test point within one week, review recent dietary modifications, physical activity interventions and pharmacologic interventions - If average BGL over one week is elevated (BGL at the same time each day) consider pharmacological therapy^{90,101}

4.7 Medical nutrition therapy

The primary intervention for women diagnosed with GDM is to modify diet and physical activity.^{45,91,104-107} The aim is to improve BGLs, maintain weight gain within recommended parameters, and promote a healthy and balanced lifestyle beyond pregnancy¹⁰⁸ that delays or avoids the subsequent development of type 2 diabetes.

Table 17. Medical nutrition therapy

Aspect	Consideration
Context	- Medical nutrition therapy (MNT) focuses on food choices for achieving optimal nutrition for maternal and fetal health¹⁰⁹ promoting appropriate GWG, achieving BGLs within target range and absence of ketones¹¹⁰ - There is limited evidence about which types of dietary advice are most suitable for women with GDM^{109,111} - MNT involves individualised advice based on nutritional assessment, but include as a minimum 175 g of carbohydrate per day^{110,112} and a low glycaemic index (GI) diet⁹¹ - One systematic review and meta-analysis demonstrated modified dietary interventions favourably influence birth weight¹¹¹
Supplementation	- Vitamin D supplementation has been shown to reduce the risk of GDM^{42,43} in women with low vitamin D levels (less than 50 nmol/L)⁴⁴ - Refer to Table 4. Risk reduction
Medical nutrition therapy (MNT)	- Refer women diagnosed with GDM to an accredited practising dietitian within one week of diagnosis¹¹³ - Consider telehealth consultation if necessary - Provide dietary advice that is culturally appropriate and individualised¹¹³ - Provide written information about: - Healthy eating (e.g. avoiding ultra-processed foods, increasing fibre intake and eating minimally processed foods) - Meeting the nutritional requirements of pregnancy (five food groups) - Carbohydrate foods and influence on BGLs - Aim for carbohydrate intake above 175 g per day^{114,115}, spread evenly and tailored to individual needs - GI and influence on BGLs¹¹⁴ - Weight gain during pregnancy - Dietary restriction sufficient to cause weight loss is not recommended - Safe foods for pregnancy - Label reading - Maintenance of a food diary
Special consideration	- If woman has had bariatric surgery refer to specialist team for dietary advice: - Regarding monitoring and supplementation of macro and micronutrients - At the end of each trimester at a minimum
Schedule of dietetic visits	- Appointments may be in person, or by phone, telehealth or email - Consider minimum schedule of dietetic appointments recommended by American Dietetic Association Nutrition Practice Guidelines¹¹³ - One hour initial counselling session - Two review appointments (minimum) one week after initial visit and then within 2–3 weeks¹¹³ - Additional reviews scheduled 2–3 weekly based on clinical need - One postnatal follow up - Further review is recommended if pharmacological treatment is initiated - Women who receive at least three dietetic appointments are less likely to require pharmacotherapy¹¹⁶

4.8 Physical activity

Assess each woman individually and tailor recommendations for physical activity to suit her abilities and clinical circumstances.

Table 18. Physical activity

Aspect	Consideration
Context	- Physical activity is recognised as a helpful adjunctive therapy for GDM^{106,113} - Women with GDM may experience greater blood glucose uptake and therefore lower BGLs through increased insulin sensitivity - Both aerobic and resistance training are beneficial¹¹⁷
Intensity	- Assess levels of current physical activity¹¹⁷ - If minimal, increase duration of moderate physical activity slowly - If already more active, maintain or lower intensity during pregnancy rather than attempting to progress to higher levels - Intensity can be assessed using rating of perceived exertion scales¹¹⁷ - Physical activity of moderate intensity enables the woman to talk, but not sing whilst exercising¹¹⁷ - Refer to Appendix D: Exercise and exertion for a guide to target heart rate ranges by age and BMI, and rating of perceived exertion
Duration	- Recommend 30 minutes of physical activity on most days of the week^{113,118} - Physical activity may be broken into shorter periods of at least 10 minute periods of moderate effort¹¹⁹
Type	- Physical activity can include aerobic exercise (e.g. walking, stationary cycle, swimming, aquatic activities, conditioning machines, prenatal exercise classes) and light or moderate resistance exercises^{118,120} - Discuss modifications to the physical activity program as pregnancy progresses (particularly in the third trimester as the body's centre of gravity is altered) - Avoid activities that^{117,119,120} - Involve lying flat on the back - Increase the risk of falling or abdominal trauma, or require frequent changes in direction (e.g. contact sports, most racquet sports, horseback riding, water skiing) - Add extra load to the pelvic floor (e.g. bouncing or jumping) - Are at extreme altitudes (e.g. scuba diving, mountain climbing)
Recommendation	- Advise women that moderate physical activity is associated with a range of health benefits, improves BGLs and is not associated with adverse outcomes^{106,117,118} - Growing body of evidence it may reduce the need for pharmacological intervention¹⁰⁶ - Advise women to¹²⁰: - Avoid dehydration during and after physical activity - Wear loose light clothing to avoid over heating - Not to exercise when hungry, unwell or with an elevated temperature - Record daily activity and duration - Avoid exercising in high temperatures and humidity - Discuss contraindications and indications to stop physical activity - Refer to Table 19. Physical activity cautions and contraindications

4.8.1 Physical activity cautions and contraindications

Table 19. Physical activity cautions and contraindications

Aspect	Consideration
Contra-indications¹¹⁸	• Contraindications to physical activity include (but are not necessarily limited to) the following conditions: - o Hemodynamically significant heart conditions - o Restrictive lung conditions - o Incompetent cervix/cerclage - o Multiple gestation at risk for premature labour - o Persistent second or third trimester bleeding - o Placenta praevia after 26 weeks gestation - o Premature labour during the current pregnancy - o Ruptured membranes - o Pre-eclampsia - o Intrauterine growth restriction
Cease physical activity and seek advice from care provider^{118,120}	• Advise women to stop physical activity and contact their health care provider if they are concerned and/or experience any of the following: - o High heart rate - o Dyspnoea prior to or during exertion - o Dizziness, faintness, nausea - o Headache - o Decreased fetal movements - o Uterine contractions, vaginal bleeding, amniotic fluid leakage - o Back or pelvic pain - o Chest pain - o Muscle weakness - o Calf pain or swelling or sudden swelling of ankles, hands and/or face • Refer to Appendix D: Exercise and exertion

5 Pharmacological therapy

Before commencing pharmacological glycaemic therapy, initiate BGL self-monitoring and review results. Individualise the period of BGL monitoring based on clinical circumstances and the degree of hyperglycaemia. Individualise decisions about medication commencement. Consider:

- Gestational age (e.g. anticipated date of birth, or if early pregnancy, hyperglycaemia requiring intensive management to achieve euglycaemia)
- Degree and pattern of hyperglycaemia (fasting or postprandial) to inform most appropriate type of pharmacological therapy
- Fetal growth (macrosomia or small for gestational age) and AC
- Maternal preference

5.1 Metformin

Table 20. Metformin

Aspect	Consideration
Context	• Women prefer metformin to insulin¹²¹ • Women who do not achieve optimal BGLs with lifestyle modification (MNT and physical activity) have traditionally been started on insulin¹²² • There is adequate evidence to consider the use of metformin as a treatment option in GDM^{5,121,123} • Metformin crosses the placenta, but no evidence of teratogenesis^{121,123} • Short term data on safe use in pregnancy and fetal development reassuring¹²¹ • Long term follow up data of children exposed in utero is limited¹²¹ ◦ Impact of increased subcutaneous fat¹²⁴, systolic blood pressure, fasting glucose and increased height and weight is uncertain¹²¹ • Metformin when compared to insulin is effective at lowering blood glucose, and is safe for pregnant women and their fetuses¹²¹⁻¹²³ • Up to 50% of women with GDM treated with metformin will require supplemental insulin to achieve glycaemic targets¹²⁵ • Lower rates of severe hypoglycaemia were found in the newborn babies of women who used metformin than in women using insulin¹²²
Indications	• Average BGL over one week is elevated (BGL monitored at the same time each day) after consideration of dietary and physical activity factors • USS shows incipient fetal macrosomia (AC above the 75th percentile) at diagnosis or accelerating fetal growth to 95th percentile • Mild overall elevated BGL or elevated fasting BGL
Potential side effects	• Nausea, loss of appetite¹²⁶ • Diarrhoea¹²⁶; vomiting¹²⁶ • Malabsorption of vitamin B12¹²⁶ (generally if longer term therapy) • May be associated with preterm birth prior to 37 weeks gestation¹²⁷
Education	• Advise woman to take metformin after a meal¹²⁶
Contraindications	• Conditions that may alter renal function¹²⁶ • Severe hepatic impairment¹²⁶ • FGR or SGA on USS • Persistent nausea and vomiting or other intolerable gastrointestinal effects • Consider ceasing if woman develops pre-eclampsia • Lactic acidosis • Severe sepsis
Administration	• Discuss with woman about metformin crossing the placenta and being a category C drug** in Australia • Commencement dose: 500 mg oral daily with food • Maximum dose: 2500mg (SR) or 2000 g (XR) oral daily¹²⁶⁻¹²⁸ • Titrate dose according to BGLs • Review BGLs within three days of commencement

*Refer to an Australian pharmacopoeia for complete drug information

** Category C drug Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. [Source TGA 2020 July 1 <https://www.tga.gov.au>]

5.2 Insulin therapy

Table 21. Insulin therapy

Aspect	Consideration
Context	- Insulin therapy is safe to use in pregnancy¹²⁹⁻¹³¹ - Rapid acting analogues preferred for control of postprandial hyperglycaemia due to effects of more stable glycaemia and greater flexibility than human insulin¹³² - There is no evidence for superiority of a specific insulin type or insulin regimen for GDM⁸⁹ - Approximately 27% of women diagnosed with GDM will require insulin therapy¹³³
Indications	- Hyperglycaemia in excess of targets despite optimisation of non-pharmacological therapies¹⁴ and/or metformin - Maternal preference
Potential side effects	- Hypoglycaemia¹²⁹ - Local (injection site) allergic reactions - Systemic reaction (e.g. skin eruptions, oedema^{9,134})
Combination therapy	Insulin added to metformin can improve BGLs¹²⁷
Commencement	- Consult with expert clinician for calculating doses and ordering appropriate insulin therapy - Individualise dose for each woman as requirements vary - Provide details on how to seek advice if woman has any concerns with insulin therapy - Review BGLs with woman (e.g. by phone or email) within three days post insulin commencement - Refer to 5.2.1 Insulin type by glycaemic abnormality for type of insulin - Consider dietitian review to ensure appropriate carbohydrate intake
Titration	- Insulin requirements may be anticipated to rise throughout the third trimester as a result of increasing maternal insulin resistance - Tends to plateau at 36–38 weeks gestation¹³⁵ - Insulin dose can be titrated every two to three days as required with increments of 2–4 units (no greater than 20% dose increase) until targets are met, or the woman experiences hypoglycaemia more than 2–3 times per week or any episode of severe hypoglycaemia¹³⁵

*Refer to an Australian pharmacopoeia for complete drug information

5.2.1 Insulin type by glycaemic abnormality

Table 22. Insulin type by glycaemia abnormality

Abnormality	Suggested insulin type	Action profile
Elevated fasting glucose	Single bedtime injection of intermediate-acting insulin* will often suffice	Onset 1.5 hours Peak 4–12 hours Duration Up to 24 hours
Postprandial hyperglycaemia	Mealtime rapid acting insulin*	Onset 10–20 mins Peak 1–3 hours Duration 3–5 hours
Fasting and postprandial hyperglycaemia	- Basal-bolus insulin regimen - Mealtime rapid acting and bedtime intermediate-acting insulin* or	As for elevated fasting glucose and postprandial hyperglycaemia
	Twice daily mixed insulin* (if woman is reluctant to inject four times per day)	Onset 30 minutes Peak 2–12 hours Duration 24 hours

*Refer to an Australian pharmacopoeia for complete drug information

5.3 Hypoglycaemia

Fasting BGLs tend to decrease in pregnancy and levels of 3.5 mmol/L may be physiologically normal and asymptomatic. Hypoglycaemia is uncommon in women with GDM, particularly those not receiving pharmacological therapy. In the absence of symptoms of hypoglycaemia, confirm the accuracy of results prior to initiating treatment.

Table 23. Hypoglycaemia in women receiving glucose lowering medication

Aspect	Consideration
Definitions	• Mild hypoglycaemia: - o BGL less than 4.0 mmol/L and - o May or may not be associated with symptoms of a low blood glucose level • Severe hypoglycaemia: - o BGL is very low, generally less than 3.0 mmol/L and - o May be associated with confusion and potentially loss of consciousness - o Third party assistance may be required by the woman to manage the episode
Causes	• Excess physical activity • Too much insulin • Missed, delayed or inadequate carbohydrate with meal¹²⁹ • Alcohol intake (decreases blood glucose)¹²⁹
Symptoms¹²⁹	• Hunger • Light headedness/headache • Sweating/shaking/weakness • Tingling around the lips • Irritability • Blurred vision • Severe hypoglycaemia can lead to confusion and loss of consciousness and requires urgent medical treatment
Treatment	• Consume one 15 g serve of fast acting carbohydrates¹³⁶ (one of the following) - o 5–7 glucose jellybeans or - o Glass of soft drink (not diet) or - o Half a glass of fruit juice or - o Lucozade® 100 mL or - o 3 heaped teaspoons of sugar or honey dissolved in water • If after 15 minutes symptoms persist or BGL remains less than 4.0 mmol/L repeat one serve of fast acting carbohydrates¹³⁶ • Do not over-treat with fast acting carbohydrates as this may lead to rebound hyperglycaemia • When BGL is 4.0 mmol/L or above eat longer lasting carbohydrate¹³⁶ - o Eat a snack (e.g. sandwich or crackers, glass of milk) or usual meal if within 30 minutes - o Avoid over treatment of hypoglycaemia resulting in hyperglycaemia - o Document BGL and time of hypoglycaemic episode
Hypoglycaemia prevention	• Plan to eat regular meals with adequate carbohydrate serves • Be prepared and carry a food snack at all times (including while exercising) • Aim to take long or intermediate acting insulin at the same time each day • Identify causal factors of the hypoglycaemic episode and avoid/mitigate for the future • Carry blood glucose meter at all times so BGL can be checked if symptoms present

5.4 Education for safe self-administration of insulin therapy

Table 24. Education for safe self-administration of insulin

Aspect	Consideration
Safety	• Ideally provided by a credentialled diabetes educator or clinician trained in teaching self-administration of insulin¹³⁷ • Individual sessions (rather than group sessions) are preferable • Confirm type of insulin and dose ordered
Demonstrate	• Insulin delivery device • Applying needle to device • Priming device and dialling dose • Injection sites and rotation • Self-injection technique • Needle size • Degree of injection angle (if required) • Use of skin fold (if required)
Discussion points	• Hand washing • Insulin action and profile • Timing of injection • Recognition of hypoglycaemia symptoms and treatment ◦ Refer to Table 23. Hypoglycaemia in women receiving glucose lowering medication • Potential side effects • Safe disposal of sharps • Safe driving¹³⁸ • Storage and handling of insulin • Expiry of insulin (opened and unopened) • Confirm and update NDSS registration to enable access to free insulin needles • Travelling—NDSS card or letter authorising woman to carry insulin and needles in hand luggage¹³⁸

6 Birthing

The decision on timing and mode of birth is primarily intended to minimise the risk of intrapartum complications associated with the birth of a LGA or macrosomic infant.¹³⁹

6.1 Considerations for birth

Table 25. Considerations for birth

Aspect	Consideration
Context	- There is little quality evidence to inform management between induction of labour (IOL) at term, expectant management or CS¹⁴⁰ - In one single centre study¹⁴¹ (n=200), IOL at 38 weeks gestational age reduced birth weight (3,446 g versus 3,672 g; $p < 0.01$) and rates of macrosomia (15 versus 27%; $p=0.05$) compared to expectant management, with no increase in the rate of CS (25% in IOL group versus 31% in expectant management group; $p=0.43$) - The GINEXMAL multicentre randomised controlled trial (RCT) found no difference in birth outcomes regardless of active versus expectant management (n=425) with no difference in the incidence of CS (21% versus 22.3%)¹⁴²
Fetal weight	- Degree of maternal hyperglycaemia is related to the risk of excessive fetal growth^{143,144} - Macrosomia increases the risk of perinatal birth trauma and shoulder dystocia, including severe perineal tears, fractures to the baby and brachial plexus injuries¹⁴ - Clinical assessment and obstetric USS estimation of fetal weight can be used effectively to exclude macrosomia - Prediction of accelerated fetal growth or LGA on USS biometry may have significant margins of error^{145,146}
Antenatal corticosteroids	If steroids are required for fetal lung maturity, monitor BGLs and consider admission and intensified insulin therapy
Communication	- Specific topics for discussion with the woman include: - Implications of GDM on birthing specific to her circumstances - Intrapartum management recommendations (if required) - Requirements for administration of pharmacological therapy (if any) when birth approaches/labour commences [refer to Section Table 27. Pharmacotherapy as birth approaches] - Document, regularly review and involve other members of health care team (e.g. anaesthetist if indicated) - Refer to Queensland Clinical Guidelines <i>Standard care guideline</i>²⁸

6.1.1 Birth

Table 26. Birth

Aspect	Consideration
Timing of birth	• If well managed with MNT and no fetal macrosomia or other complications, wait for spontaneous labour (unless there are other indications for IOL)⁸⁸ • If suspected fetal macrosomia or other complications, consider birth from 38+0–39+0 weeks gestation^{21,34,88} • RANZCOG recommend suspected fetal macrosomia alone is not an indication for IOL before 39+0 weeks gestation ◦ Insufficient evidence that benefits of reducing shoulder dystocia risk outweigh early birth harm² • Consider risk of stillbirth with prolongation of pregnancy versus risk of preterm birth⁸⁸ • Pharmacological therapy alone is not an indication for birth before term • In most cases, women with optimal BGLs who are receiving pharmacological therapy do not require expedited birth before 39+0 weeks gestation⁸⁸
Induction of labour	• There is no clear evidence that women with GDM and a normally grown fetus should have different indications for IOL than women without GDM¹⁴⁷ • Consider concomitant complications (e.g. pre-eclampsia, growth restriction, obesity) that influence the risk of stillbirth when counselling women about expectant management versus IOL
Mode of birth	• If fetal weight is estimated at: ◦ Less than 4000 g, vaginal birth is usually appropriate ◦ 4000–4500 g, consider other individual factors (e.g. maternal stature, obstetric and birth history, previous macrosomia with or without shoulder dystocia, limitations of estimating fetal weight) ◦ More than 4500 g, consider elective CS^{2,88}—counsel women about the risks and benefits⁸⁸ ▪ Insufficient data to determine if CS indicated to reduce birth trauma risk¹⁴⁶ • Women with GDM are at increased risk of instrumental extraction at birth due to shoulder dystocia compared to spontaneous vaginal birth¹⁴⁸ • X-ray pelvimetry is not recommended¹⁴⁸

6.2 Pharmacotherapy as birth approaches

- Develop and document an individual pharmacotherapy plan considering the woman's individual circumstances
- If the woman is receiving intravenous insulin infusion for unstable BGL do not cease while glucose being administered when nil by mouth during the preoperative period

Table 27. Pharmacotherapy as birth approaches

Labour/birth	Metformin	Insulin
Spontaneous onset	• Cease metformin when in established labour	• Titrate insulin requirements according to BGL during labour
IOL	• Cease metformin when in established labour	If morning IOL commencement • Eat early morning breakfast • Administer usual dose of rapid acting insulin with breakfast • Omit long or intermediate acting insulin in the morning • Cease subcutaneous insulin when in established labour If afternoon/evening IOL commencement • Administer usual dose of rapid acting insulin with evening meal • If not in established labour, administer long or intermediate acting insulin before bedtime • Cease subcutaneous insulin when in established labour
Caesarean section	• Cease metformin evening before elective procedure	• Administer usual rapid and intermediate/long acting insulin the night before ◦ Consider individual woman's clinical situation including fasting BGL ◦ May require reduced dose of intermediate/long acting insulin • Monitor BGL • Fast for six hours prior to elective CS ◦ If fasting, omit all subcutaneous insulin on the morning of the CS

6.3 Intrapartum monitoring

Refer to the Queensland Clinical Guideline *Intrapartum fetal surveillance*.¹⁴⁹

Table 28. Intrapartum monitoring

Aspect	Monitoring
All women	• Aim for BGL 4.0–7.0 mmol/L irrespective of GDM therapy during pregnancy¹⁵⁰ • Ensure adequate glucose during labour to meet high energy requirements • Recommend continuous cardiotocography (CTG) during labour for women with GDM if during pregnancy¹⁵¹ ◦ Insulin or metformin required or ◦ Suboptimal BGLs or ◦ Fetal macrosomia
If non-pharmacological therapy during pregnancy	• BGL on arrival then 4 hourly monitoring ◦ Increase frequency according to BGLs ◦ Refer to Table 29. Intrapartum BGL monitoring • It is uncommon to experience hypoglycaemia or to require insulin
If pharmacological therapy during pregnancy	• BGL on arrival, then 2 hourly monitoring ◦ Increase frequency according to BGLs ◦ Refer to Table 29. Intrapartum BGL monitoring ◦ If required, insulin requirements are commonly lower during labour (usually no insulin necessary)

6.4 Intrapartum BGL management

The aim of intrapartum BGL management is to maintain optimal BGLs while avoiding hypoglycaemia. Maintain BGL during labour 4–7 mmol/L to minimise risk of neonatal hypoglycaemia.¹

Table 29. Intrapartum BGL monitoring

Aspect	Consideration
BGL more than 7.0 mmol/L	• If BGL greater than 7.0 mmol/L seek medical review • Consider clinical circumstances (e.g. stage of labour, imminency of birth, intake, effects of increased stress levels) when determining management • Management may include: ◦ Repeat BGL in 1 hour and reassess or ◦ Consider insulin infusion
BGL less than 4.0 mmol/L or symptomatic	• Cease insulin therapy • If symptomatic, treat hypoglycaemia and repeat BGL in 15 minutes • If asymptomatic and receiving insulin, repeat BGL in 15 minutes and reassess • If asymptomatic and not receiving insulin, repeat BGL in 1 hour and reassess (or earlier if becomes symptomatic) • Refer to Section 5.3 Hypoglycaemia

6.4.1 Insulin infusion

An insulin infusion is **rarely** needed during labour for women with GDM. Seek expert opinion before commencement. If no local policy or procedure exists, the following example insulin infusion regimen may be considered, but individualised doses are required.

Table 30. Example insulin infusion

Aspect	Recommendation	
IV Infusion	• Administer via infusion pump	
Mainline	• Commence 1 litre glucose containing fluid at 80 mL/hour, for example: ◦ Glucose 4%/sodium chloride 0.18% or ◦ Compound sodium lactate (Hartmann's solution) with glucose 5%	
Sideline	• Add 50 units (0.5 mL of 100 units per mL) neutral insulin to 49.5 mL of sodium chloride 0.9% to give a concentration of 1 unit/mL • Flush line with insulin admixture down to connection port	
BGL monitoring	• Commence and adjust insulin infusion according to BGL • Monitor BGL hourly while insulin infusion being administered • Medical review two hours after commencement to assess individual requirements	
Insulin infusion starting doses and BGL targets	Starting doses only—adjust according to individual needs	
	BGL (mmol/L)	Insulin infusion
	4.0 mmol/L or less	• Discontinue infusion • Notify and review by medical officer
	4.1–6.0 mmol/L	• 1 mL/hour = 1 unit/hour
	6.1–8.0 mmol/L	• 2 mL/hour = 2 unit/hour
	8.1–10.0 mmol/L	• 3 mL/hour = 3 unit/hour
	10.1 mmol/L or more	• Continue infusion • Notify and review by medical officer

7 Postpartum care

Provide routine maternal postpartum care appropriate to the clinical circumstances, including continued BGL monitoring depending on therapy during the pregnancy.

Table 31. Postpartum BGL monitoring

Aspect	Consideration
Context	- There is limited evidence/consensus regarding the frequency and type of postpartum BGL monitoring for women with GDM who have been well managed during pregnancy with non-pharmacological therapy - Postpartum target BGL for all women with GDM is less than or equal to 8.0 mmol/L (preprandial)
Non-pharmacological therapy	Cease BGL monitoring after birth
Pharmacological therapy	- Cease pharmacological therapy (metformin and insulin) immediately after birth (vaginal or CS) - Continue BGL monitoring four times per day for 24 hours (preprandial and before bed) - If all preprandial BGLs 4.0–8.0 mmol/L discontinue monitoring 24 hours after birth - If BGL greater than or equal to 4.0 mmol/L and diet tolerated, cease mainline IV fluids - If diet not tolerated or BGL less than 4.0 mmol/L, seek medical review - Consider glucose 4%/sodium chloride 0.18% or compound sodium lactate (Hartmann's solution) with glucose 5% IL IV 12 hourly
Elevated BGL	- If any preprandial BGL is greater than 8.0 mmol/L - Seek medical review - Continue BGL monitoring - Insulin is rarely required postpartum - If required, prescribe lower dose than required during pregnancy
Newborn baby care	- Keep baby warm - Support early feeding and skin to skin contact within first hour of life - Monitor BGL - Refer to Queensland Clinical Guidelines <i>Newborn hypoglycaemia</i>¹⁵²

7.1 Breastfeeding

Table 32. Breastfeeding

Aspect	Consideration
Context	• Women with GDM are less likely to breastfeed (75% versus 86%) and continue for a shorter duration (9 versus 17 weeks) compared with women without GDM¹⁵³ ◦ These values are even lower in women with GDM who require insulin therapy or who are obese^{153,154} • Breastfeeding has short and long term benefits for women who have had GDM^{1,155-157} ◦ Longer duration of breastfeeding reduces risk of type 2 diabetes in women who have had GDM¹⁵⁸ ▪ One study found breastfeeding duration of three or more months reduced the risk of type 2 diabetes and delayed development of type 2 diabetes a further 10 years, compared with breastfeeding less than 3 months¹⁵⁹ ◦ Exclusive breastfeeding for greater than one month reduces the recurrence rate of GDM¹⁵⁷ ◦ Metabolic adaptations during lactation can reverse atherogenic and diabetogenic effects of pregnancy for the woman with DIP¹⁶⁰ • Metformin and insulin are both safe for breastfeeding women • Refer to Table 13. Special considerations
Recommendation	• Support and encourage women to breastfeed • Provide advice and information to the woman about the maternal and baby benefits of breastfeeding including: ◦ Reducing risk of developing diabetes for the woman¹ and baby^{1,85} ◦ Prevention of neonatal hypoglycaemia ◦ Reducing risk of childhood obesity¹ • Offer early additional skilled lactation support and assistance with breastfeeding to women with GDM¹⁵⁴ • Refer to the Queensland Clinical Guideline: <i>Establishing breastfeeding</i>¹⁶¹
Post-bariatric surgery⁷¹	• Recommend breastfeeding • Monitor maternal macro- and micronutrients during lactation under care of specialist team and general practitioner

7.2 Discharge planning

Consider routine criteria to inform readiness for discharge.

Table 33. Discharge planning

Aspect	Consideration	
Weight	- Optimise postpartum and inter-pregnancy weight - Risk of developing type 2 diabetes is greatly affected by body weight - Significant increase in the odds of GDM occurring in subsequent pregnancies with each unit of BMI gained <i>between</i> pregnancies¹⁶²	
	BMI gain	Increased odds of future GDM
	1–1.9 kg/m ²	1.7
	2.0–2.9 kg/m ²	2.5
	3 kg/m ² or more	3.4
	- Women who are overweight or obese at their index pregnancy, but who subsequently lose weight (approximately 2.0 kg/m²) lower their future risk of GDM by almost 80%¹⁶³ - Support women to maintain a healthy lifestyle that includes physical activity and maintenance of a healthy weight range and BMI after birth¹⁶⁴	
Referral and follow-up	- Provide written advice to the woman's primary health carer(s) (e.g. GP, midwife, diabetes educator) about maternal and/or neonatal outcomes - Advise women to see their GP to be screened for persistent diabetes at 6–12 weeks postpartum using the OGTT and non-pregnancy diagnostic criteria^{7,88,165,166} - The National Gestational Diabetes Register sends reminders to women and their GPs to have diabetes checks postpartum - Women with a history of GDM require lifelong screening for the development of: - Type 2 diabetes/IGT/IFG - If contemplating another pregnancy recommend OGTT or HbA1c annually^{7,165} - If no further pregnancies planned recommend diabetes or pre-diabetes screening at least every 3 years¹⁶⁵ - Cardiovascular disease - Women with a history of GDM found to have pre-diabetes, require lifestyle intervention counselling to assist in preventing progression to type 2¹	
Contraception	- Suggest contraception until postpartum OGTT test is completed and continue until planning for next pregnancy - Discuss risks and benefits of methods and women's preferences - Long acting reversible contraceptives provide a high degree of reliability and efficacy (e.g. progesterone injection, intrauterine device (IUD), progesterone implant) - Consider increased risk of metabolic syndrome - If other risk factors (e.g. hypertension) suggest IUD or progesterone only agent⁴	
Future pregnancies	- Advise women to plan in consultation with healthcare provider - Provide advice about weight management before next pregnancy - Screen prior to conception - Manage glucose abnormality - Recommend folic acid supplementation¹ - Perform early glucose testing in a future pregnancy	
Post bariatric surgery	- Refer woman for band adjustment once lactation is established to minimise risk of micronutrient deficiencies⁷¹ - Continue specialist dietary advice to optimise macro- and micronutrient supplementation and dietary intake - Refer to Queensland Clinical Guidelines <i>Obesity in pregnancy</i>⁷²	

References

1. Feig D, Berger H, Donovan L, Godbout A, Kader T, Keely E, et al. Diabetes and pregnancy. *Canadian Journal of Diabetes* 2018;42:S255-S82.
2. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Diagnosis and management of suspected fetal macrosomia. Best Practice Statement C-Obs. [Internet]. 2020 [cited 2020 November 6]. Available from: <https://www.ranzcog.edu.au>.
3. Chiefari E, Arcidiacono B, Foti D, Brunetti A. Gestational diabetes mellitus: an updated overview. *Journal of Endocrinological Investigation* 2017;40(9):899-909.
4. World Health Organisation. Classification of hyperglycaemia first detected in pregnancy. [Internet]. 2013 [cited 2020 January 30]. Available from: <https://www.who.int>.
5. Hod M, Kapur A, McIntyre HD. Evidence in support of the International Association of Diabetes in Pregnancy study groups' criteria for diagnosing gestational diabetes mellitus worldwide in 2019. *American Journal of Obstetrics and Gynecology* 2019;221(2):109-16.
6. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care* 2020;43(Suppl 1):S183-92.
7. Nankervis A, McIntyre H, Moses R, Ross G, Callaway L, Porter C, et al. ADIPS consensus guidelines for the testing and diagnosis of gestational diabetes mellitus in Australia and New Zealand. [Internet]. 2014 [cited 2019 November 14]. Available from: <https://www.adips.org>.
8. The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *New England Journal of Medicine* 2008;358(19):1991-2002.
9. Brown J, Grzeskowiak L, Williamson K, Downie MR, Crowther CA. Insulin for the treatment of women with gestational diabetes. *Cochrane Database of Systematic Reviews*. 2017 [cited 2020 January 31]; Issue 11. Art. No.: CD012037.(11) DOI:10.1002/14651858.CD012037.pub2.
10. Tieu J, McPhee AJ, Crowther CA, Middleton P, Shepherd E. Screening for gestational diabetes mellitus based on different risk profiles and settings for improving maternal and infant health. *Cochrane Database of Systematic Reviews*. [Internet]. 2017 [cited 2020 April 23]; 8 Art No. CD007222 DOI:10.1002/14651858.CD007222.pub4.
11. Lowe WL, Jr, Scholtens DM, Lowe LP, Kuang A, Nodzenski M, Talbot O, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. *Journal of American Medical Association* 2018;320(10):1005-16.
12. Berger H, Gagnon R, Sermer M. Guideline No. 393: Diabetes in pregnancy. *Journal of Obstetrics and Gynaecology Canada* 2019;41(12):1814-25.e1.
13. Kong L, Nilsson I, Gissler M, Lavebratt C. Associations of maternal diabetes and body mass index with offspring birth weight and prematurity. *Journal of American Medical Association Pediatrics* 2019;173(4):371-8.
14. Durnwald A. Gestational diabetes mellitus: glycemic control and maternal prognosis. [Internet]. Waltham, MA: UpToDate Inc; 2020 [cited 2020 July 7]. Available from: <https://www.uptodate.com>.
15. Dirar A, Doupis J. Gestational diabetes from A to Z. *World Journal of Diabetes* 2017;5(12):484-511.
16. Battarbee A, Venkatesh K, Aliaga S, Boggess K. The association of pregestational and gestational diabetes with severe neonatal morbidity and mortality. *Journal of Perinatology* 2020;40:232-9.
17. Billionnet C, Mitancher D, Weill A, Nizard J, All F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. *Diabetologia* 2017;60:636-44.
18. National Health and Medical Research Council. National pregnancy guidelines. [Internet]. 2018 [cited 2020 January 30]. Available from: www.nhmrc.gov.au.
19. International Association of the Diabetes and Pregnancy Study Groups (IADPSG) Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33(3):676-82.
20. The Royal Australian College of Obstetricians and Gynaecologists. Diagnosis of gestational diabetes (GDM). College Statement C-Obs 7. [Internet]. 2017 [cited 2020 January 30]. Available from: <https://ranzcog.edu.au>.
21. Hod M, Kapur A, Sacks D, Hadar E, Agarwal G, Di Renzo G, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. *International Journal of Gynecology and Obstetrics* 2015;131(S3):S173-211.
22. Australian Institute of Health and Welfare. Australia's mothers and babies data visualisations. [Internet]. 2020 [cited 2020 July 3]. Available from: <https://www.aihw.gov.au>.
23. Queensland Health Perinatal Data Collection Statistical Services Branch. GDM data 2014-2019. 2020 [cited 2020 January 31].
24. Australian Institute of Health and Welfare. Incidence of gestational diabetes in Australia. [Internet]. 2019 [cited 2019 November 21]. Available from: <https://www.aihw.gov.au>.
25. Diabetes Australia Ltd. Understanding pre-diabetes. [Internet]. 2016 [cited 2020 January 20]. Available from: <https://www.diabetesaustralia.com.au>.
26. Scottish Intecollegiate Guideline Network. Management of diabetes: a national clinical guideline. SIGN publication no. 116. [Internet]. 2017 [cited 2020 January 27]. Available from: <http://www.sign.ac.uk>.
27. Willcox JC, Campbell KJ, van der Pligt P, Hoban E, Pidd D, Wilkinson S. Excess gestational weight gain: an exploration of midwives' views and practice. *BioMed Central Pregnancy Childbirth* 2012;12:102.
28. Queensland Clinical Guidelines. Standard care. Guideline No. MN18.50-V1-R23. [Internet]. Queensland Health. 2018. [cited 2020 January 30]. Available from: <http://www.health.qld.gov.au>
29. Homer CSE. Models of maternity care: evidence for midwifery continuity of care. *Medical Journal of Australia* 2016;205(8):370-4.
30. Sandall J, Soltani H, Gates S, Shennan A, Devane D. Midwife-led continuity models versus other models of care for childbearing women. *Cochrane Database of Systematic Reviews*. [Internet]. 2017 [cited 2020 July 2]; Issue 4. Art. No.: CD004667 DOI:10.1002/14651858.CD004667.pub5.
31. Tracy SK, Hartz DL, Tracy MB, Allen J, Forti A, Hall B, et al. Caseload midwifery care versus standard maternity care for women of any risk: M@NGO, a randomised controlled trial. *Lancet* 2013;382(9906):1723-32.
32. Sina M, Cade TJ, Flack J, Nolan CJ, Rajagopal R, Wong V, et al. Antenatal models of care for women with gestational diabetes mellitus: vignettes from an international meeting. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. [Internet]. 2020 [cited 2020/03/10]. Available from: <https://doi.org/10.1111/ajo.13144>.
33. Broughton C. An overview of the management of diabetes from pre-conception, during pregnancy and in the postnatal period. *Clinical Medicine* 2019;19(5):399-402.
34. National Institute of Health and Clinical Excellence (NICE). Diabetes in pregnancy. Quality Standard 109. [Internet]. 2016 [cited 2019 November 14]. Available from: <http://www.nice.org.uk>.
35. Fallon A, Dunne F. Breastfeeding practices that support women with diabetes to breastfeed. *Diabetes Research and Clinical Practice* 2015;110(1):10-7.

36. National Diabetes Services Scheme. National gestational diabetes register. [Internet]. 2020 [cited 2020 July 23]. Available from: <https://www.ndss.com.au>.
37. British Medical Journal Best Practice. Gestational diabetes mellitus. [Internet]. 2019 [cited 2019 November 14]. Available from: <https://bestpractice.bmj.com>.
38. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to Type 2 diabetes: a global perspective. *Curr Diab Rep* 2016;16(1):7.
39. Hirsch L, Berger H, Okby R, Ray JG, Geary M, McDonald SD, et al. Incidence and risk factors for gestational diabetes mellitus in twin versus singleton pregnancies. *Archives of Gynecology and Obstetrics* 2018;298(3):579-87.
40. Song C, Li J, Leng J, Ma RC, Yang X. Lifestyle intervention can reduce the risk of gestational diabetes: a meta-analysis of randomized controlled trials. *Obesity Reviews* 2016;17(10):960-9.
41. Callaway LK, McIntyre HD, Barrett HL, Foxcroft K, Tremellen A, Lingwood BE, et al. Probiotics for the prevention of gestational diabetes mellitus in overweight and obese women: findings from the SPRING double-blind randomized controlled trial. *Diabetes Care* 2019;42(3):364.
42. Palacios C, Kostiuik LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews*. [Internet]. 2019 [cited 2020 July 1]; Issue 7. Art. No.: CD008873 DOI:10.1002/14651858.CD008873.pub4.
43. Griffith RJ, Alsweiler J, Moore AE, Brown S, Middleton P, Shepherd E, et al. Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. *Cochrane Database of Systematic Reviews*. [Internet]. 2020 [cited 2020 October 1]; Issue 6. Art. No.: CD012394.(6) DOI:10.1002/14651858.CD012394.pub3.
44. Corcoy R, Mendoza LC, Simmons D, Desoye G, Mathiesen ER, Kautzky-Willer A, et al. Re: Vitamin D and gestational diabetes mellitus: a systematic review based on data free of Hawthorne effect. *British Journal of Obstetrics and Gynaecology* 2018;125(10):1338-9.
45. Shepherd E, Gomersall J, Tieu J, Hans S, Crowther CA, Middleton P. Combined diet and exercise interventions for preventing gestational diabetes mellitus. *Cochrane Database of Systematic Reviews*. [Internet]. 2017 [cited 2020 April 23]; Issue 11 Art. No.: CD010443. DOI:10.1002/14651858.CD010443.pub3.
46. Yu Y, Xie R, Shen C, Shu L. Effect of exercise during pregnancy to prevent gestational diabetes mellitus: a systematic review and meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine* 2018;31(12):1632-7.
47. Muktabhant B. Diet or exercise, or both, for preventing excessive weight gain in pregnancy (Review). *Cochrane Database of Systematic Reviews*. [Internet]. 2015 [cited 2020 July 3]; Issue 6. Art. No.: CD007145. DOI:10.1002/14651858.CD007145.pub3.
48. Brown J, Martis R, Hughes B, Rowan J, Crowther CA. Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes. *Cochrane Database of Systematic Reviews*. [Internet]. 2017 [cited 2020 July 7]; Issue 1. Art. No.: CD011967 DOI:10.1002/14651858.CD011967.pub2.
49. Han S, Crowther C, P M. Interventions for pregnant women with hyperglycaemia not meeting gestational diabetes and type 2 diabetes diagnostic criteria. *Cochrane Database of Systematic Reviews*. [Internet]. 2012 [cited 2020 July 24]; Issue 1. Art. No.: CD009037 DOI:10.1002/14651858.CD009037.pub2.
50. Martis R, Brown J, Alsweiler J, Crawford TJ, Crowther CA. Different intensities of glycaemic control for women with gestational diabetes mellitus. *Cochrane Database of Systematic Reviews*. [Internet]. 2016 [cited 2020 July 3]; Issue 4. Art. No.: CD011624(4) DOI:10.1002/14651858.CD011624.pub2.
51. Veeraswamy S, Vijayam B, Gupta K, Kapur A. Gestational diabetes: the public health relevance and approach. *Diabetes Research and Clinical Practice* 2012;97(350-8).
52. Varner MW, Rice M, Landon M, Casey B, Reddy U, Wapner, et al. Pregnancies after the diagnosis of mild gestational diabetes mellitus and risk of cardiometabolic disorders. *Obstetrics and Gynecology* 2017;129(2):273-80.
53. Wang Y-Y, Liu Y, Li C, Lin J, Liu X-M, Sheng J-Z, et al. Frequency and risk factors for recurrent gestational diabetes mellitus in primiparous women: a case control study. *BioMed Central Endocrine Disorders* 2019;19(1):22.
54. Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. *American Journal of Obstetrics and Gynecology*. [Internet]. 2010 [cited 2020 November 11]; DOI:<https://doi.org/10.1016/j.ajog.2010.05.032>.
55. Barker J, Su F, Alwan NA. Risk factors for type 2 diabetes after gestational diabetes: a population-based cohort study. *The Lancet* 2017;390:S21.
56. Beharier O, Shoham-Vardi I, Pariente G, Sergienko R, Kessous R, Baumfeld Y, et al. Gestational diabetes mellitus is a significant risk factor for long-term maternal renal disease. *The Journal of Clinical Endocrinology & Metabolism* 2015;100(4):1412-6.
57. Mitancher D, Burguet A, Simeoni U. Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health. *Journal of Pediatrics* 2014;164(3):445-50.
58. Martin B, Sacks DA. The global burden of hyperglycemia in pregnancy – trends from studies in the last decade. *Diabetes Research and Clinical Practice* 2018;145:17-9.
59. Schraw JM, Langlois PH, Lupo PJ. Comprehensive assessment of the associations between maternal diabetes and structural birth defects in offspring: a phenotype-wide association study. *Annals of Epidemiology*. [Internet]. 2021 [cited 2021 February 24]. Available from: <http://www.sciencedirect.com/science/article/pii/S1047279720302878> DOI:doi.org/10.1016/j.annepidem.2020.08.006.
60. Stacey T, Tennant PWG, McCowan LME, Mitchell EA, Budd J, Li M, et al. Gestational diabetes and the risk of late stillbirth: a case-control study from England, UK. *British Journal of Obstetrics and Gynaecology* 2019;126(8):973-82.
61. Josefson JL, Catalano PM, Lowe WL, Scholtens DM, Kuang A, Dyer AR, et al. The joint associations of maternal BMI and glycemia with childhood adiposity. *The Journal of Clinical Endocrinology & Metabolism* 2020;105(7):2177-88.
62. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. *Annals of Internal Medicine* 2013;159(2):123-9.
63. Zhu Y, Hedderson MM, Feng J, Quesenberry C, Ferrara A. 1423-P: Diagnostic performance of fasting glucose, insulin, and HOMA-IR in the first and second trimesters in predicting gestational diabetes. *Diabetes* 2019;68(Supplement 1):1423-P.
64. Saccone G, Khalifeh A, Al-Kouatly HB, Sendek K, Berghella V. Screening for gestational diabetes mellitus: one step versus two step approach. A meta-analysis of randomized trials. *The Journal of Maternal-Fetal & Neonatal Medicine* 2018;1-9.
65. Schneid WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. *Diabetes Care* 2000;23(3):339-44.
66. Lab Tests Online. Glucose. [Internet]. 2020 [cited 2020 January 16]. Available from: <https://www.labtestsonline.org.au>.
67. Queensland Clinical Guidelines. Gestational diabetes (during COVID-19 pandemic). Guideline No. MN15.33-V1-R20 (update). [Internet]. Queensland Health. 2020. [cited 2020 December 3]. Available from: <http://www.health.qld.gov.au>
68. Gutvirtz G, Alexander C, Scheiner E. Bariatric surgery and its impacts on gestational diabetes. In: Rajendram R, editor. *Nutrition and diet in maternal diabetes*. [Internet]. Cham, Switzerland: Springer Nature; 2017. p. 207-26.
69. Kulshreshtha B, Gupta N, Ganie MA, Ammini AC. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis. *Gynecological Endocrinology* 2012;28(10):823-6.

70. The Royal College of Pathologists of Australasia. Glucose tolerance test. [Internet]. 2019 [cited 2020 July 10]. Available from: <https://www.rcpa.edu.au>.
71. Shawe J, Ceulemans D, Akhter Z, Neff K, Hart K, Heslehurst N, et al. Pregnancy after bariatric surgery: consensus recommendations for periconception, antenatal and postnatal care. *Obesity Reviews* 2019;20(11):1507-22.
72. Queensland Clinical Guidelines. Obesity in pregnancy. Guideline No. MN 15.14-V5.R20 [Internet]. Queensland Health. 2020. [cited 2020 November 12]. Available from: <http://www.health.qld.gov.au>
73. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. *Int J Gynaecol Obstet* 2019;145 Suppl 1(Suppl 1):1-33.
74. Queensland Clinical Guidelines. Hypertension and pregnancy. Guideline No. MN21.13-V8-R26. [Internet]. Queensland Health. 2020. [cited 2021 February 24]. Available from: <http://www.health.qld.gov.au>
75. Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c $\geq 5.9\%$ (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. *Diabetes Care* 2014;37(11):2953-9.
76. Balaji V, Madhuri BS, Ashalatha S, Sheela S, Suresh S, Seshiah V. A1C in gestational diabetes mellitus in Asian Indian women. *Diabetes Care* 2007;30(7):1865-7.
77. Fong A, Serra AE, Gabby L, Wing DA, Berkowitz KM. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. *American Journal of Obstetrics and Gynecology*. [Internet]. 2014 [cited 2020 August 5]; 21(641):e1-7.
78. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *New England Journal of Medicine* 2005;352(24):2477-86.
79. Glazier JD, Hayes DJL, Hussain S, D'Souza SW, Whitcombe J, Heazell AEP, et al. The effect of Ramadan fasting during pregnancy on perinatal outcomes: a systematic review and meta-analysis. *BioMed Central Pregnancy and Childbirth* 2018;18(1):421-.
80. Afandi BO, Hassanein MM, Majd LM, Nagelkerke NJD. Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study. *BMJ Open Diabetes Research & Care* 2017;5(1):e000470-e.
81. Black MH, Sacks DA, Xiang AH, Lawrence JM. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. *Diabetes Care* 2013;36(1):56-62.
82. National Health and Medical Research Council. Australian Dietary Guidelines. Canberra: National Health and Medical Research Council. 2013.
83. Diabetes Australian Guideline Development Consortium. National evidence based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. [Internet]. 2009 [cited 2020 February 10]. Available from: www.diabetesaustralia.com.au.
84. Coolen JC, Verhaeghe J. Physiology and clinical value of glycosuria after a glucose challenge during pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2010;150(2):132-6.
85. Forster DA, Moorhead AM, Jacobs SE, Davis PG, Walker SP, McEgan KM, et al. Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial. *The Lancet* 2017;389(10085):2204-13.
86. Forster DA, Jacobs S, Amir LH, Davis P, Walker SP, McEgan K, et al. Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised controlled trial. *BMJ Open* 2014;4(10):e006571.
87. Queensland Clinical Guidelines. Term small for gestational age. Guideline No. MN16.16-V4-R21. [Internet]. Queensland Health. 2016. [cited 2020 November 9]. Available from: <http://www.health.qld.gov.au>
88. American College of Obstetricians and Gynecologists. Gestational diabetes: Practice Bulletin No. 190. *Obstetrics and Gynecology* 2018;131(2):406-8.
89. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. *New England Journal of Medicine* 2008;358(19):1991-2002.
90. Kjos SL, Schaefer-Graf UM. Modified therapy for gestational diabetes using high-risk and low-risk fetal abdominal circumference growth to select strict versus relaxed maternal glycemic targets. *Diabetes Care* 2007;30 Suppl 2:S200-5.
91. Denney J, Quinn K. Gestational diabetes: underpinning principles, surveillance, and management. *Obstetrics and Gynecology Clinics of North America* 2018;45:299-314.
92. Nash CM, Woolcott C, O'Connell C, Armson BA. Optimal timing of prenatal ultrasound in predicting birth weight in diabetic pregnancies. *Journal of Obstetrics and Gynaecology Canada* 2020;42(1):48-53.
93. McIntyre HD, Baskerville C, Oats J. Gestational diabetes. In: Bandeira F, Gharib H, Golbert A, Faria LG, editors. *Endocrinology and Diabetes: A Problem-Oriented Approach*. New York: Springer Science+Business Media; 2014.
94. National Diabetes Services Scheme. Gestational diabetes: caring for yourself and your baby (V7). [Internet]. 2019 [cited 2020 July 1]. Available from: <https://www.ndss.com.au>.
95. Tabassam N, Sadaqat F, Mahmood KT, Zaka M. Prevention and management of gestational diabetes. *Journal of Pharmaceutical Science and Technology* 2010;2(12):404-10.
96. Magon N, Seshiah V. Gestational diabetes mellitus: non-insulin management. *Indian Journal of Endocrinology Metabolism* 2011;15(4):284-93.
97. Queensland Clinical Guidelines. Hypoglycaemia in a newborn baby Guideline No. C19.8-1-V3-R24 [Internet]. Queensland Health. 2019. [cited 2020 November 12]. Available from: <http://www.health.qld.gov.au>
98. Groeller H, Lowe S, Worsley A, Jenkins A. Does exercise have a role in the management of gestational diabetes mellitus? *Obstetric Medicine* 2010;3(4):133-8.
99. Spahn JM, Reeves RS, Keim KS, Laquatra I, Kellogg M, Jortberg B, et al. State of the evidence regarding behavior change theories and strategies in nutrition counseling to facilitate health and food behavior change. *Journal of the American Dietetic Association* 2010;110(6):879-91.
100. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *New England Journal of Medicine* 2009;361(14):1339-48.
101. Hernandez TL, Anderson MA, Chartier-Logan C, Friedman JE, Barbour LA. Strategies in the nutritional management of gestational diabetes. *Clinical Obstetrics and Gynecology* 2013;56(4):803-15.
102. Therapeutic Goods Administration (TGA). Glucose flash monitoring. [Internet]. Canberra: Australian Government; 2020 [cited 2020 July 17]. Available from: <https://www.tga.gov.au>.
103. Diabetes Australia. Flash glucose monitoring. [Internet]. 2020 [cited 2020 July 17]. Available from: <https://www.diabetesaustralia.com.au>.
104. Shyam S, Ramandas A. Treatments with low glycaemic index diets in gestational diabetes. In: Rajendram R, Preedy V, Patel V, editors. *Nutrition and diet in maternal diabetes: an evidence based approach*. [Internet]. Switzerland: Springer International Publishing AG; 2018. p. 237-51.

105. de Seymour J, McKenzie E, Baker P. Using the food metabolome to understand the relationship between maternal diet and gestational diabetes. In: Rajendram R, Preedy V, Patel V, editors. Diet in maternal diabetes an evidence-based approach. Switzerland: Springer International 2017. p. 263-74.
106. Guelfi K, Halse R, Newnham J. The role of exercise in the management of gestational diabetes. In: Rajendram R, Preedy V, Patel V, editors. Switzerland: Springer International Publishing 2017. p. 289-300.
107. Kgosidialwa O, Egan AM, Carmody L, Kirwan B, Gunning P, Dunne FP. Treatment with diet and exercise for women with gestational diabetes mellitus diagnosed using IADPSG criteria. *Journal of Clinical Endocrinology and Metabolism* 2015;100(12):4629-36.
108. Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al. Interventions to reduce or prevent obesity in pregnant women: a systematic review. *Health Technology Assessment*. [Internet]. 2012 [cited 2020 July 23]; 16(31). Available from: <http://www.ncbi.nlm.nih.gov> DOI:10.3310/hta16310.
109. Hernandez TL, Brand-Miller JC. Nutrition therapy in gestational diabetes mellitus: time to move forward. *Diabetes Care* 2018;41(7):1343.
110. American Diabetes Association. Position statement: nutrition recommendations and interventions for diabetes. *Diabetes Care* 2008;31(Supplement 1):S61-S78.
111. Yamamoto JM, Kellett JE, Balsells M, García-Patterson A, Hadar E, Solà I, et al. Gestational diabetes mellitus and diet: a systematic review and meta-analysis of randomized controlled trials examining the impact of modified dietary interventions on maternal glucose control and neonatal birth weight. *Diabetes Care* 2018;41(7):1346.
112. Moreno-Castilla C, Hernandez M, Mauricio D. Low-carbohydrate diet for the treatment of gestational diabetes mellitus. In: Rajendram R, Preedy V, Patel V, editors. Nutrition and diet in maternal diabetes: an evidence-based approach. Switzerland: Springer International Publishing AG; 2017. p. 253-61.
113. Duarte-Gardea M, Gonzales-Pacheco D, Reader D, Thomas A, Wang S, Gregory R, et al. Academy of nutrition and dietetics gestational diabetes evidence-based nutrition practice guideline. *Journal of the Academy of Nutrition and Dietetics* 2018;118(9):1719-42.
114. Hernandez T, Mande A, Barbour L. Nutrition therapy within and beyond gestational diabetes. *Diabetes research and clinical practice* 2018;145(November):39-50.
115. Academy of Nutrition and Dietetics. Gestational diabetes: executive summary of recommendations. [Internet]. 2016 [cited 2020 December 9]. Available from: <https://www.andean.org>.
116. Meloncelli N, Barnett A, de Jersey S. An implementation science approach for developing and implementing a dietitian led model of care for gestational diabetes: a pre-post study. *BioMed Central Pregnancy and Childbirth*. [Internet]. 2020 [cited 2020 November 9]; DOI:<https://doi.org/10.1186/s12884-020-03352-6>.
117. Colberg SR, Castorino K, Jovanovic L. Prescribing physical activity to prevent and manage gestational diabetes. *World Journal of Diabetes* 2013;4(6):256-62.
118. Sports Medicine Australia. Pregnancy and exercise. Fact sheet. [Internet]. n.d. [cited 2020 May 11].
119. United States Department of Health Human and Services. Physical activity guidelines for Americans 2nd edition. [Internet]. 2018 [cited 2020 July 23]. Available from: <https://health.gov>.
120. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Exercise during pregnancy. [Internet]. 2016 [cited 2020 May 11]. Available from: <https://rancog.edu.au>.
121. Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariassen A, Donovan L. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. *Diabetic Medicine* 2017;34(1):27-36.
122. Landi SN, Radke S, Boggess K, Engel SM, Stürmer T, Howe AS, et al. Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. *Pharmacoepidemiology and Drug Safety* 2019;28(12):1609-19.
123. Kumar R, Lowe J, Thompson-Hutchison F, Steinberg D, Shah B, Lipscombe L, et al. Implementation and evaluation of the "Metformin First" protocol for management of gestational diabetes. *Canadian Journal of Diabetes* 2019;43(8):554-9.
124. Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. *Scandinavian Journal of Clinical and Laboratory Investigation* 2012;72(7):570-5.
125. Ryu RJ, Hays KE, Hebert MF. Gestational diabetes mellitus management with oral hypoglycemic agents. *Seminars in Perinatology* 2014;38(8):508-15.
126. Australian Medicines Handbook. Metformin. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; 2020 [cited 2020 June 3]. Available from: <http://www.amhonline.amh.net.au>.
127. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. *New England Journal of Medicine* 2008;358(19):2003-15.
128. Therapeutic Guidelines. Metformin. [Internet]. Melbourne Australia 2019 [cited 2020 November 12]. Available from: www.tga.org.au.
129. Australian Medicines Handbook. Insulin. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; 2020 [cited 2020 July 7]. Available from: <http://www.amhonline.amh.net.au>.
130. Moses RG, Casey SA, Quinn EG, Cleary JM, Tapsell LC, Milosavljevic M, et al. Pregnancy and glycemic index outcomes study: effects of low glycemic index compared with conventional dietary advice on selected pregnancy outcomes. *American Journal of Clinical Nutrition* 2014;99(3):517-23.
131. Therapeutic Goods Administration (TGA). Insulin lispro. [Internet]. 2020 [cited 2020 June 3]. Available from: <https://www.tga.gov.au>.
132. Bacon S, Feig DS. Glucose targets and insulin choice in pregnancy: what has changed in the last decade? *Current Diabetes Reports* 2018;18(10):77.
133. Gilmarin AB, Ural SH, Repke JT. Gestational diabetes mellitus. *Reviews in Obstetrics and Gynecology* 2008;1(3):129-34.
134. Therapeutic Goods Administration TGA. Insulin lispro (humalog cartridges) consumer medicine information. [Internet]. 2019 [cited 2020 June 3]. Available from: <https://www.tga.gov.au>.
135. Donovan P, McIntyre D. Drugs for gestational diabetes. *Australian Prescriber* 2010;33(5):141-4.
136. Diabetes Australia. Hypoglycaemia. [Internet]. 2020 [cited 2020 July 7]. Available from: <https://www.diabetesaustralia.com.au>.
137. Diabetes Australia. Insulin. [Internet]. 2020 [cited 2020 July 7]. Available from: <https://www.diabetesaustralia.com.au>.
138. National Diabetes Services Scheme. Driving and diabetes. [Internet]. 2020 [cited 2020 July 1]. Available from: <https://www.ndss.com.au>.
139. Maso G, Piccoli M, Parolin S, Restaino S, Alberico S. Diabetes in pregnancy: timing and mode of delivery. *Current Diabetes Reports* 2014;14(7):506.
140. Biesty LM, Egan AM, Dunne F, Dempsey E, Meskell P, Smith V, et al. Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants. *Cochrane Database Systematic Reviews*. 2018 [cited 2020 June 22]; Issue 1. Art. No.: CD012910(1):CD012910 DOI:10.1002/14651858.CD012910.
141. Kjos SL, Henry OA, Montoro M, Buchanan TA, Mestman JH. Insulin-requiring diabetes in pregnancy: a randomized trial of active induction of labor and expectant management. *American Journal of Obstetrics and Gynecology* 1993;169(3):611-5.

142. Alberico S, Erenbourg A, Hod M, Yogev Y, Hadar E, Neri F, et al. Immediate delivery or expectant management in gestational diabetes at term: the GINEXMAL randomised controlled trial. *British Journal of Obstetrics and Gynecologists* 2017;124(4):669-77.
143. Pénager C, Bardet P, Timsit J, Lepercq J. Determinants of the persistency of macrosomia and shoulder dystocia despite treatment of gestational diabetes mellitus. *Heliyon*. [Internet]. 2020 [cited 2020 July 1]:e03756 DOI:10.1016/j.heliyon.2020.e03756.
144. Riskin A, Garcia-Prats J. Infants of women with diabetes. [Internet]. Waltham MA: UpToDate Inc; 2020 [cited 2020 July 1]. Available from: <https://www.uptodate.com>.
145. Caughey A, Werner EF, Barss V. Gestational diabetes mellitus: obstetric issues and management. [Internet]. Waltham, MA: UpToDate Inc; 2019 [cited 2020 February 10]. Available from: <https://www.uptodate.com>.
146. Mozurkewich E. Fetal macrosomia. In: Moore L, editor. *Diabetes in pregnancy: the complete guide to management*. Switzerland: Springer International Publishing AG; 2018.
147. Coates D, Makris A, Catling C, Henry A, Scarf V, Watts N, et al. A systematic scoping review of clinical indications for induction of labour. *PloS one*. [Internet]. 2020 [cited 2020 July 1]; 15:e0228196 DOI:10.1371/journal.pone.0228196.
148. Garabedian C, Deruelle P. Delivery (timing, route, peripartum glycemic control) in women with gestational diabetes mellitus. *Diabetes & Metabolism* 2010;36(6 Pt 2):515-21.
149. Queensland Clinical Guidelines. Intrapartum fetal surveillance. Guideline No. MN19.15-V7-R24. [Internet]. Queensland Health. 2019. [cited 2020 July 1]. Available from: <http://www.health.qld.gov.au>
150. Blumer I, Hadar E, Hadden DR, Jovanovic L, Mestman JH, Hassan Murad M, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism* 2013;98:4227-49.
151. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Intrapartum fetal surveillance Clinical Guideline 4th edition. [Internet]. 2019 [cited 2020 January 30]. Available from: <https://ranzcog.edu.au>.
152. Queensland Clinical Guidelines. Hypoglycaemia-newborn. Guideline No. MN19.8-V6-R24. [Internet]. Queensland Health. 2019. [cited 2020 July 1]. Available from: <http://www.health.qld.gov.au>
153. Much D, Beyerlein A, Rossbauer M, Hummel S, Ziegler AG. Beneficial effects of breastfeeding in women with gestational diabetes mellitus. *Molecular Metabolism* 2014;3(3):284-92.
154. Matias SL, Dewey KG, Quesenberry CP, Gunderson EP. Maternal prepregnancy obesity and insulin treatment during pregnancy are independently associated with delayed lactogenesis in women with recent gestational diabetes mellitus. *American Journal of Clinical Nutrition* 2014;99(1):115-21.
155. You H, Lei A, Xiang J, Wang Y, Luo B, Hu J. Effects of breastfeeding education based on the self-efficacy theory on women with gestational diabetes mellitus: a CONSORT-compliant randomized controlled trial. *Medicine*. [Internet]. 2020 [cited 2020 July 21]; DOI:10.1097/MD.00000000000019643.
156. Bartick MC, Jegier BJ, Green BD, Schwarz EB, Reinhold AG, Stuebe AM. Disparities in breastfeeding: impact on maternal and child health outcomes and costs. *Journal of Pediatrics* 2017;181:49-55.e6.
157. Suarez-Easton S, Berkovich I, Tal A, Zoabi R, Rubin H, Rom E, et al. Effect of lactation on the recurrence of gestational diabetes mellitus. *American Journal of Obstetrics and Gynecology* 2018;218(1, Supplement):S591-S2.
158. Ley SH, Chavarro JE, Li M, Bao W, Hinkle SN, Wander PL, et al. Lactation duration and long-term risk for incident type 2 diabetes in women with a history of gestational diabetes mellitus. *Diabetes Care* 2020;43(4):793-8.
159. Ziegler AG, Wallner M, Kaiser I, Rossbauer M, Harsunen MH, Lachmann L, et al. Long-term protective effect of lactation on the development of type 2 diabetes in women with recent gestational diabetes mellitus. *Diabetes* 2012;61(12):3167-71.
160. De Bortoli J, Amir LH. Is onset of lactation delayed in women with diabetes in pregnancy? A systematic review. *Diabetic Medicine* 2016;33(1):17-24.
161. Queensland Clinical Guidelines. Establishing breastfeeding. Guideline No. MN16.19-V3-R21. [Internet]. Queensland Health. 2016. [cited 2020 January 30]. Available from: <http://www.health.qld.gov.au>
162. Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. *Diabetic Medicine* 2014;31(3):292-301.
163. Kim SY, Sharma AJ, Sappenfield W, Wilson HG, Salihu HM. Association of maternal body mass index, excessive weight gain, and gestational diabetes mellitus with large-for-gestational-age births. *Obstetrics and Gynecology* 2014;123(4):737-44.
164. Nielsen KK, Kapur A, Damm P, de Courten M, Bygbjerg IC. From screening to postpartum follow-up - the determinants and barriers for gestational diabetes mellitus (GDM) services, a systematic review. *Biomed Central Pregnancy Childbirth* 2014;14:41.
165. American Diabetes Association. Position statement: standards of medical care in diabetes 2014. *Diabetes Care* 2014;37(Supplement 1):S14-S80.
166. National Diabetes Services Scheme. Gestational diabetes: caring for yourself and your baby. [Internet]. 2019 [cited 2020 July 1]. Available from: <https://www.ndss.com.au>.

Appendix A: Conversion table for HbA1c measurement

Worldwide (including Australia), HbA1c measurement and reporting has been standardised using Systeme International (SI) units.

HbA1c as percentage	HbA1c in mmol/mol
5.0	31
6.0	42
6.5	48
7.0	53
8.0	64
9.0	75
10.0	86
11.0	97
12.0	108

Appendix B: Gestational weight gain

The National Academy of Medicine (formerly the Institute of Medicine) have recommended weight gain for women with singleton and twin pregnancies.

Pre-pregnancy BMI (kg/m ²)	Mean rate of gain 2nd and 3rd trimester (kg/week)	Recommended range of total gain (kg)
Singleton pregnancy		
Less than 18.5	0.51	12.5 to 18
18.5 to 24.9	0.42	11.5 to 16
25.0 to 29.9	0.28	7 to 11.5
Greater than or equal to 30	0.22	5 to 9
Twin pregnancy		
Less than 18.5	N/A	N/A
18.5 to 24.9	N/A	17-25
25.0 to 29.9	N/A	14-23
Greater than or equal to 30	N/A	11-19

Source: National Academy of Medicine. Weight gain during pregnancy. 2009 [cited 2020 May 11]. Available from: <https://www.nap.edu>

Appendix C: Antenatal schedule of care

Testing

Consideration	Result	Plan
Risk factors for GDM: ☐ 1st trimester: OGTT or HbA1c ☐ If after 1st trimester: OGTT	OGTT (mmol/L) Fasting: _____ 1 hour: _____ 2 hour: _____ HbA1c (mmol/mol) _____	If normal: OGTT at 24–28 weeks gestation or If indicated: Commence GDM care
Previous bariatric surgery and diabetes history/other risk factors: ☐ 1st trimester: HbA1c ☐ If after 1st trimester: fasting BGL	HbA1c (mmol/mol) _____ BGL (mmol/L) _____	If normal: Self-monitoring at 24–28 weeks gestation or If indicated: Commence GDM care
No risk factors or history: ☐ 24–28 weeks OGTT	OGTT (mmol/L) Fasting: _____ 1 hour: _____ 2 hour: _____	If indicated: Commence GDM care

At initial GDM diagnosis

Discuss/Review/Refer	Considerations
☐ Review history	Previous GDM, medications
☐ Diabetes educator consult	Within 1 week of diagnosis for GDM education
☐ Dietitian review	Within 1 week of diagnosis
☐ Psychosocial assessment/support	Refer as required
☐ BGL self-monitoring	Commence self-monitoring
☐ BMI (pre-pregnancy)	Discuss healthy weight gain targets
☐ Lifestyle advice	Physical activity, healthy eating, smoking cessation
☐ Baseline ultrasound scan (USS)	At 28–30 weeks gestation
☐ Initial laboratory investigations	☐ Serum creatinine
☐ If <i>Diabetes in Pregnancy</i>	☐ Optometrist/ophthalmologist review for diabetic retinopathy ☐ Microalbuminuria for diabetic nephropathy

Each Visit

Discuss/Review/Refer	Considerations
☐ Clinical surveillance	Complications (e.g. pre-eclampsia)
☐ Weigh	Weight gain trends, diet, exercise
☐ Test urine	Investigate ketonuria, proteinuria
☐ Review BGL self-monitoring record	Patterns, trends and mean BGL
☐ Psychosocial assessment/support	Refer as required
☐ Fetal growth and wellbeing (including AC)	USS 2–4 weekly as indicated (after 28–30 weeks)
☐ If pharmacological therapy commenced	☐ Follow-up contact within 3 days ☐ Diabetes educator (weekly) ☐ Dietitian review
☐ Review suitability of model of care	☐ Low risk GDM ☐ Diabetic clinic ☐ Obstetric ☐ Other _____
☐ Review next contact requirements (increase frequency if: suboptimal BGL, early diagnosis, diabetes in pregnancy, pharmacological therapy commenced)	☐ Fortnightly until 38 weeks ☐ Fortnightly until 36 weeks ☐ Weekly until birth ☐ Other _____

Appendix D: Exercise and exertion

Target heart rate ranges for pregnant women

Consider individual clinical circumstances when prescribing physical activity. Use the following heart rate ranges as a guide only.

Maternal age (years)	Fitness level or BMI	Heart rate range (beats/minute)
< 20		140–155
20–29	Low	129–144
	Active	135–150
	Fit	145–160
	BMI > 25 kg/m ²	103–124
30–39	Low	128–144
	Active	130–145
	Fit	140–156
	BMI > 25 kg/m ²	101–120
40+		125–140

< less than; > greater than

Adapted from: Sports Medicine Australia. Pregnancy and exercise. Fact sheet. n.d. [cited 2020 May 11]. Available from: www.sma.org.au.

Rating of perceived exertion

Rating of perceived exertion (RPE) is a widely used and reliable indicator to monitor and guide exercise intensity. The scale allows individuals to subjectively rate their level of exertion during exercise or exercise testing.

Rating of perceived exertion		Talk test
6		Can talk normally
7	Very, very light	
8		
9	Very light	
10		
11	Fairly light	Can talk but not sing
12		
13	Somewhat hard	
14		
15	Hard	Hard to talk
16		
17	Very hard	
18		
19	Very very hard	
20	Maximum exertion	Don't work this hard

Adapted from: Sports Medicine Australia. Pregnancy and exercise. Fact sheet. n.d. [cited 2020 May 11]. Available from: www.sma.org.au.

Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads

Ms Alison Barry, Credentialed Diabetes Educator/ Midwife, Royal Brisbane and Women's Hospital

Professor Rebecca Kimble, Pre-eminent Staff Specialist, Obstetrics & Gynaecology, Royal Brisbane and Women's Hospital

Professor David McIntyre, Pre-eminent Staff Specialist, Director Obstetric Medicine/Endocrinologist, Mater Mother's Hospital

QCG Program Officer

Ms Stephanie Sutherns

Peer Review Panel

Dr Helen Barrett, Endocrinologist/Obstetric Physician, Mater Mother's Hospital Brisbane

Ms Gabrielle Fleming, Consumer Representative, Maternity Consumer Network

Ms Anndrea Flint, Neonatal Nurse Practitioner, Redcliffe Hospital

Professor Helen Liley, Neonatologist, Mater Mother's Hospital

Dr Annabelle Lamprecht, Endocrinologist/Obstetric Physician, Royal Brisbane and Women's Hospital

Ms Gemma MacMillan, Director of Midwifery, Torres Strait

Dr Scott Petersen, Maternal-Fetal Medicine Specialist, Mater Mother's Hospital

Dr Sophie Poulter, Endocrinologist/Obstetric Physician, Sunshine Coast University Hospital

Dr Hilary Powlesland, Senior Dietician, Royal Brisbane and Women's Hospital and Statewide Bariatric Service

Ms Rhonda Taylor, Clinical Midwifery Consultant, Townsville University Hospital

Dr Shelley Wilkinson, Principle Research Fellow, Dietetics, University of Queensland

Queensland Clinical Guidelines Team

Professor Rebecca Kimble, Director

Ms Jacinta Lee, Manager

Ms Stephanie Sutherns, Clinical Nurse Consultant

Ms Cara Cox, Clinical Nurse Consultant

Ms Emily Holmes, Clinical Nurse Consultant

Ms Janene Rattray, Clinical Nurse Consultant

Steering Committee

Funding

This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health